


ISSN- 0974-3618 (Print)  
ISSN- 0974-360X (Online)

# Research Journal of Pharmacy and Technology

RJPT

An International Peer-reviewed  
Journal of Pharmaceutical Sciences



## EDITOR IN CHIEF

---



DR. MRS. MONIKA S. DAHARWAL

[Editor In Chief](#)

A & V Publications, RJPT House, Lokmanya GrihNirman Society, Rohanipuram, In-front of Sector- 1, Pt. Deendayal Upadhyay Nagar, Raipur 492 010. (CG) India

Email: [editor.rjpt@gmail.com](mailto:editor.rjpt@gmail.com)

[Home Page](#)

## ASSOCIATE EDITOR

---



MARWAN MAHMOOD SALEH

[Associate Editor](#)

Anbar-Ramadi- Habbaniya- 4-4-17

Email: [bio.marwan92@gmail.com](mailto:bio.marwan92@gmail.com)

[Home Page](#)



DHANANJAY BABANRAO DESHMUKH

[Associate Editor](#)

Ashvin college of pharmacy manchi hill ashvi Bk sangamner Ahmednagar

Email: [dhananjaydeshmukh777@gmail.com](mailto:dhananjaydeshmukh777@gmail.com)

[Home Page](#)



DR.RER.NAT ARLI ADITYA PARIKES

[Associate Editor](#)

Department of Bioinformatics School of Life Sciences Indonesia International Institute for Life Sciences Jl. Pulomas Barat Kav.88 Jakarta 13210

Email: [arli.parikesit@i3l.ac.id](mailto:arli.parikesit@i3l.ac.id)

[Home Page](#)



DR G KUMARASWAMY

[Associate Editor](#)

Dr.Kumara Swamy. Gandla Prof.& HeadDept.of Pharmaceutical AnalysisCare College of Pharmacy, Warangal, Telangana.Mobile: +91-9000973789

Email: [kumaraswamy.gandla@gmail.com](mailto:kumaraswamy.gandla@gmail.com)

[Home Page](#)



HARDIK PATHAK

[Associate Editor](#)

222 pashupatinath nagar, jaipur

Email: [hardikaeshu@gmail.com](mailto:hardikaeshu@gmail.com)

[Home Page](#)



MARIIA SHANAIDA

[Associate Editor](#)

46001, Ternopil, Voli Str., 1. Ukraine

Email: [shanyda-mi@ukr.net](mailto:shanyda-mi@ukr.net)

[Home Page](#)



DR. G. MANIKANDAN

[Associate Editor](#)

Dr. G.Manikandan Assistant Professor Department of Botany Sri Kaliswari College (Autonomous)  
Sivakasi - 626130 Tamil Nadu India

Email: [rgmani.19@gmail.com](mailto:rgmani.19@gmail.com)

[Home Page](#)



DR.S.MOHANASUNDARAM

[Associate Editor](#)

Department of Biochemistry, Sri Sankara Arts and Science College (Autonomous), Kanchipuram -  
631561, Tamilnadu, India

Email: [sbmohan2007@gmail.com](mailto:sbmohan2007@gmail.com)

[Home Page](#)



DR SHAEESTA K. BHAVIKATTI

[Associate Editor](#)

College of Dentistry, King Khalid University, Abha, Saudi Arabia

Email: [drshaeesta@gmail.com](mailto:drshaeesta@gmail.com)

[Home Page](#)



DR KARTEEK ESWARA

[Associate Editor](#)

T2,staff quarters, ksr Institutions, ksr kalvi nagar, Tiruchengode-637215, Tamilnadu

Email: [karteekeswara@gmail.com](mailto:karteekeswara@gmail.com)

[Home Page](#)

DR. CHUKWUEBUKA EMMANUEL UMEYO

[Associate Editor](#)



Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmaceutical Sciences, Nnamdi Azikiwe University, Awka, Anambra State, Nigeria  
Email: [ec.umeyor@unizik.edu.ng](mailto:ec.umeyor@unizik.edu.ng)  
[Home Page](#)



DR. PRANAV KUMAR PRABHAKAR  
[Associate Editor](#)  
Department of Transdisciplinary Research, Division of Research & Development, Lovely Professional University, Phagwara, Punjab, India-144402  
Email: [prabhakar.iitm@gmail.com](mailto:prabhakar.iitm@gmail.com)  
[Home Page](#)



EBAA ADNAN AZOOZ  
[Associate Editor](#)  
Iraq, Najaf  
Email: [ebaaadnan.ed12p@uokufa.edu.iq](mailto:ebaaadnan.ed12p@uokufa.edu.iq)  
[Home Page](#)



PROF. VIJAY D. MENDHULKAR  
[Associate Editor](#)  
Prof. and Head, Department of Botany The Institute of Science 15- Madame Cama Road Fort, Mumbai  
Email: [drmendhulkar@gmail.com](mailto:drmendhulkar@gmail.com)  
[Home Page](#)



DR. SUBRAT KUMAR PATTANAYAK  
[Associate Editor](#)  
Department of Chemistry NIT Raipur -492010, India  
Email: [skpiitbbs@gmail.com](mailto:skpiitbbs@gmail.com)  
[Home Page](#)



DR. UPENDRA PRASAD TRIPATHY  
[Associate Editor](#)  
JAYKAYPUR[PAPRI], RAYAGADA, ODISHA  
Email: [uptripathy@gmail.com](mailto:uptripathy@gmail.com)  
[Home Page](#)



SONAM BHATIA  
[Associate Editor](#)  
Dept. of Pharmaceutical Sciences, Faculty of Health Science, Sam Higginbottom University of Agriculture, Technology and Sciences, Prayagraj, India  
Email: [sonamniper.bhatia@gmail.com](mailto:sonamniper.bhatia@gmail.com)



[Home Page](#)



DR. GURJEET KAUR

[Associate Editor](#)

Amity Institute of Biotechnology Amity University Uttar Pradesh Lucknow India

Email: [gkaur@lko.amity.edu](mailto:gkaur@lko.amity.edu)

[Home Page](#)



HUSSEIN O.M. AL-DAHMOshi

[Associate Editor](#)

Iraq, Babylon Province Hilla City

Email: [dr.dahmoshi83@gmail.com](mailto:dr.dahmoshi83@gmail.com)

[Home Page](#)



DR. BISWAJIT BASU

[Associate Editor](#)

Dr. Biswajit Basu. Associate Professor. Department of Pharmaceutics. Bengal School of Technology, Sugandha, Delhi Road, Hooghly – 712 102, West Bengal India.

Email: [bbasu.pharma@gmail.com](mailto:bbasu.pharma@gmail.com)

[Home Page](#)



BIMESH KUMAR

[Associate Editor](#)

BLOCK-4B, ROOM NO 203, SCHOOL OF PHARMACEUTICAL SCIENCES, LOVELY PROFESSIONAL UNIVERSITY, PHAGWARA, PUNJAB, 144411

Email: [bimlesh1pharm@gmail.com](mailto:bimlesh1pharm@gmail.com)

[Home Page](#)



DR. BELLAMKONDA RAMESH

[Associate Editor](#)

Department of Food Technology, Vikrama Simhapuri University, Nellore, Andhra Pradesh, India-524320

Email: [rammygp@gmail.com](mailto:rammygp@gmail.com)

[Home Page](#)



K. MAHALINGAN

[Associate Editor](#)

RR College of Pharmacy, RR Nagar, Chickabanawara, Bangalore- 560090

Email: [kmahalingan@gmail.com](mailto:kmahalingan@gmail.com)

[Home Page](#)



DR. RUPESH K. GAUTAM

[Associate Editor](#)

MM School of Pharmacy, MM University, Ambala-Chandigarh Highway, Sadopur-Ambala (India)  
-134007

Email: [drrupeshgautam@gmail.com](mailto:drrupeshgautam@gmail.com)

[Home Page](#)



DR LINU MOHAN P

[Associate Editor](#)

Professor Department of Pharmacy Practice Al Shifa College of Pharmacy Perinthalmanna-  
Kerala- India

Email: [linumohanp@alshifacollegeofpharmacy.ac.in](mailto:linumohanp@alshifacollegeofpharmacy.ac.in)

[Home Page](#)



SHANKAR BALU KALBHARE

[Associate Editor](#)

YSPM'S Yashoda Technical Campus, Satara 415003

Email: [kirankal786@gmail.com](mailto:kirankal786@gmail.com)

[Home Page](#)



R.SUNDARALINGAM

[Associate Editor](#)

Assistant Professor, Department of Microbiology, Madras Christian College (Autonomous),  
Tambaram, Chennai - 600059. Tamilnadu

Email: [sundaralingam@mcc.edu.in](mailto:sundaralingam@mcc.edu.in)

[Home Page](#)



DR ANUPAM KR SACHAN

[Associate Editor](#)

Dayanand Dinanath College, Institute of Pharmacy, Kanpur Nagar, Uttar Pradesh-208027

Email: [anupamkrsachan@gmail.com](mailto:anupamkrsachan@gmail.com)

[Home Page](#)



MANIKANDAN K

[Associate Editor](#)

SRM College of Pharmacy SRM Institute of Science and Technology Kattankulathur,  
Kancheepuram

Email: [gurumani12@gmail.com](mailto:gurumani12@gmail.com)

[Home Page](#)



DR. PAVAN KUMAR

[Associate Editor](#)

Koneru Lakshmaiah Education Foundation KLEF

Email: [pavankmaths@gmail.com](mailto:pavankmaths@gmail.com)

[Home Page](#)



ASHEESH SINGH

[Associate Editor](#)

M-303, Swastik city near Pooja park, Lambha turning Narol-Ahmedabad-382405

Email: [asheesh\\_parihar@yahoo.com](mailto:asheesh_parihar@yahoo.com)

[Home Page](#)



SWARNIMA PANDEY

[Associate Editor](#)

Goel Institute of Pharmacy & Sciences ,Faizabad road lucknow 226028

Email: [yesgoldi@gmail.com](mailto:yesgoldi@gmail.com)

[Home Page](#)



DR. PARUL JOHRI

[Associate Editor](#)

C-1/167 indra nagar kanpur

Email: [pjohri@lko.amity.edu](mailto:pjohri@lko.amity.edu)

[Home Page](#)



MORTEZA SAKI

[Associate Editor](#)

Department of Microbiology, Faculty of Medicine Ahvaz Jundishapur University of Medical Sciences Ahvaz

Email: [mortezasaki1981@gmail.com](mailto:mortezasaki1981@gmail.com)

[Home Page](#)



DUMPALA LAKSHMIPRASUNA RAJESH

[Associate Editor](#)

Sumandeep Pharmacy college AT & PO: PIPARIA,WAGHODIA ROAD, TA: WAGHODIA, VADODARA- 391760

Email: [mlakshmiprasuna2015@gmail.com](mailto:mlakshmiprasuna2015@gmail.com)

[Home Page](#)

DR. S. BALASUBRAMANIYAN

[Associate Editor](#)

National Centre for Coastal Research Chennai.



Email: [sakthivelbala.s@gmail.com](mailto:sakthivelbala.s@gmail.com)  
[Home Page](#)



PROF. DR. NAGHAM MAHMOOD ALJAM  
[Associate Editor](#)  
Professor, Ph.D, Organic Chemistry , Iraq [dr.nagham\\_mj@yahoo.com](mailto:dr.nagham_mj@yahoo.com)  
Email: [dr.nagham\\_mj@yahoo.com](mailto:dr.nagham_mj@yahoo.com)  
[Home Page](#)



ARIF NUR MUHAMMAD ANSORI  
[Associate Editor](#)  
Universitas Airlangga, Surabaya, Indonesia.  
Email: [arif.nma-17@fkh.unair.ac.id](mailto:arif.nma-17@fkh.unair.ac.id)  
[Home Page](#)



DR.K.B.BHASKAR  
[Associate Editor](#)  
33B, kannadhasan street, new balaji nagar, selaiyur , chennai.  
Email: [jaibhaskar15@gmail.com](mailto:jaibhaskar15@gmail.com)  
[Home Page](#)



DIMPLE NAGPAL  
[Associate Editor](#)  
Chitkara University,Punjab  
Email: [dimplenagpal009@gmail.com](mailto:dimplenagpal009@gmail.com)  
[Home Page](#)



DR VINAYAKUMAR KADIBAGIL  
[Associate Editor](#)  
BELUR ROAD, 2ND CROSS ABHI Building  
Email: [DRVINAYKADIBAGIL@GMAIL.COM](mailto:DRVINAYKADIBAGIL@GMAIL.COM)  
[Home Page](#)



DR. ATUL KABRA  
[Associate Editor](#)  
University Institute of Pharma Sciences Chandigarh University Mohali, Punjab  
Email: [atul.kbr@gmail.com](mailto:atul.kbr@gmail.com)  
[Home Page](#)



MOHD IBRAHIM ALARAJ  
[Associate Editor](#)  
Airport St. Amman, Jordan  
Email: [ibrahim\\_naseem@yahoo.com](mailto:ibrahim_naseem@yahoo.com)  
[Home Page](#)



RAVINANDAN A P  
[Associate Editor](#)  
Mr. Ravinandan A P, M. Pharm, MBA, FSASS, (Ph.D.) Assistant Professor, Clinical Pharmacist and Research Scholar Department of Pharmacy Practice Sree Siddaganga College of Pharmacy In Collaboration with Siddaganga Hospital and Research Centre BH Road, Tumkur, Karnataka, India  
Email: [ravinandanap@gmail.com](mailto:ravinandanap@gmail.com)  
[Home Page](#)



DR. PUTTA RAJESH KUMAR  
[Associate Editor](#)  
Dr. Putta Rajesh Kumar, C/o: Amdapur X Road, Yenkapally, Moinabad, Ranga Reddy, Hyderabad, Telangana 500075 INDIA Mobile: 0-949-072-1376  
Email: [prkbpc@gmail.com](mailto:prkbpc@gmail.com)  
[Home Page](#)



DR. SRIKANTH JEYABALAN  
[Associate Editor](#)  
Department of Pharmacology Sri Ramachandra Faculty of Pharmacy Sri Ramachandra Institute of Higher Education & Research (DU) Porur, Chennai , Tamil Nadu - 600 116  
Email: [srikanth.j@sriramachandra.edu.in](mailto:srikanth.j@sriramachandra.edu.in)  
[Home Page](#)



PROF.B.RAMYA KUBER  
[Associate Editor](#)  
Prof.B.Ramya Kuber, Professor of Pharmacognosy Institute of Pharmaceutical Technology, Sri Padmavati Mahila Visvavidyalayam(Women's University), Tirupati-517502, Andhra Pradesh,India.  
Email: [rkuberpharma@yahoo.com](mailto:rkuberpharma@yahoo.com)  
[Home Page](#)



DR GOVINDH BODDETI  
[Associate Editor](#)  
Door Number: 1-1-33/A, New Venkojipalem  
Email: [govindhbd@gmail.com](mailto:govindhbd@gmail.com)  
[Home Page](#)



DR DURGESH RANJAN KAR

[Associate Editor](#)

BENGAL SCHOOL OF TECHNOLOGY A COLLEGE OF PHARMACY SUGHANDHA  
CHUCHURA DIST- HOOGHLY WEST BENGAL INDIA

Email: [durgesh176@gmail.com](mailto:durgesh176@gmail.com)

[Home Page](#)



MORTHA LAKSHMI PRASANNA

[Associate Editor](#)

VJ'S COLLEGE OF PHARMACY Diwancheruvu Rajahmundry, andhra pradesh Pin 533296

Email: [luckympharma09@gmail.com](mailto:luckympharma09@gmail.com)

[Home Page](#)



DR. GARIMA MISHRA

[Associate Editor](#)

Department of Pharmacy, College of Health Sciences, Debre Tabor University, Ethiopia

Email: [gp\\_nmr2002@yahoo.co.in](mailto:gp_nmr2002@yahoo.co.in)

[Home Page](#)



DR. PRADEEP SINGH

[Associate Editor](#)

Department of Pharmacy, College of Health Sciences, Debre Tabor University, Ethiopia

Email: [pradeep\\_2682@yahoo.co.in](mailto:pradeep_2682@yahoo.co.in)

[Home Page](#)



DR. DAVID PAUL

[Associate Editor](#)

St.James College of Pharmaceutical Sciences St.James Medical Academy River Bank,  
Chalaky Kerala, India-680307

Email: [davidpaulred@gmail.com](mailto:davidpaulred@gmail.com)

[Home Page](#)



DR.S.SASIKALA

[Associate Editor](#)

Head and Associate professor Department of Computer Science with Cognitive Systems  
Hindusthan College of Arts and Science, Coimbatore – 641028, Tamilnadu, India.

Email: [iamsasikalamohit@gmail.com](mailto:iamsasikalamohit@gmail.com)

[Home Page](#)

DR. A.K. JHA

[Associate Editor](#)



Principal, Shri Shakaracharya College of Pharma. Sciences, Bhilai CG India  
Email: [jhaak@rediffmail.com](mailto:jhaak@rediffmail.com)  
[Home Page](#)



DR. NAGHAM MAHMOOD ALJAMALI  
[Associate Editor](#)  
college Education , department , IRAQ.  
Email: [dr.nagham\\_mj@yahoo.com](mailto:dr.nagham_mj@yahoo.com)  
[Home Page](#)



DR. R. B. KAKADE  
[Associate Editor](#)  
Professor, Uni. Dept. of Pharmaceutical Sci., RTM Nagpur University, Nagpur India  
Email: [drkakde@yahoo.com](mailto:drkakde@yahoo.com)  
[Home Page](#)



WISSAM ZAM  
[Associate Editor](#)  
Al-Andalus University of Medical Sciences/Faculty of Pharmacy-Tarous, Syria  
Email: [w.zam@au.edu.sy](mailto:w.zam@au.edu.sy)  
[Home Page](#)



DR. VIBHA YADAV  
[Associate Editor](#)  
Covington, LA, USA  
Email: [editor.rjpt@gmail.com](mailto:editor.rjpt@gmail.com)  
[Home Page](#)



DR. S. ASHUTOSH KUMAR  
[Associate Editor](#)  
Department of Pharmacy, Tripura University (A Central University) Suryamaninagar, West Tripura,  
Tripura- 799022.  
Email: [ashu.mpharm2007@gmail.com](mailto:ashu.mpharm2007@gmail.com)  
[Home Page](#)



DR. U.S. MAHADEVA RAO  
[Associate Editor](#)  
Kuala Terengganu, Malaysia  
Email: [raousm@gmail.com](mailto:raousm@gmail.com)  
[Home Page](#)



CHANDRASEKARAN V M

[Associate Editor](#)

124 Technology Tower VIT University Vellore 632014 (TN)

Email: [vmcsn@yahoo.com](mailto:vmcsn@yahoo.com)

[Home Page](#)



NAEEM HASAN KHAN

[Associate Editor](#)

Faculty of Pharmacy, AIMST University, 08100 Bedong, Kedah D.A., Malaysia.

Email: [naeemhshirazi@hotmail.com](mailto:naeemhshirazi@hotmail.com)

[Home Page](#)



DR. DEEPANSH SHARMA

[Associate Editor](#)

Block 28, Room No. 202 Department of Biosciences, Lovely Professional University

Email: [deepanshsharma@gmail.com](mailto:deepanshsharma@gmail.com)

[Home Page](#)



DR. S. SARAF

[Associate Editor](#)

Professor, University Institute of Pharmacy , PT. Ravishankar Shukla University, Raipur-492010

CG India Vice- President, Pharmacy Council of India, New Delhi

Email: [shailendrasarf@rediffmail.com](mailto:shailendrasarf@rediffmail.com)

[Home Page](#)



DR. DEEPENDRA SINGH

[Associate Editor](#)

University Institute of Pharmacy Pt. Ravishankar Shukla University Raipur(C.G.)

Email: [deependraiop@gmail.com](mailto:deependraiop@gmail.com)

[Home Page](#)



DR S RAJESHKUMAR

[Associate Editor](#)

Nanotherapy Lab School of Biosciences and Technology, VIT, Vellore

Email: [ssrajeshkumar@hotmail.com](mailto:ssrajeshkumar@hotmail.com)

[Home Page](#)

VASUNDHRA KASHYAP PHD, MBA, MS





Associate Editor  
66 Lowden Avenue, Somerville, MA 02144 USA  
Email: [vk76@cornell.edu](mailto:vk76@cornell.edu)  
[Home Page](#)



ROMAN LYSIUK  
Associate Editor  
Department of Pharmacognosy and Botany, Danylo Halytsky Lviv National Medical University,  
Pekarska,69., Lviv, Ukraine, 79010  
Email: [pharmacognosy.org.ua@ukr.net](mailto:pharmacognosy.org.ua@ukr.net)  
[Home Page](#)



BEHZAD FOROUTAN  
Associate Editor  
Department of Pharmacology, School of Medicine, Shahroud University of Medical Sciences,  
Shahroud, Iran  
Email: [behzad\\_foroutan@hotmail.com](mailto:behzad_foroutan@hotmail.com)  
[Home Page](#)

## ACADAMIC EDITOR

---



DR. BHARTI AHIRWAR  
Associate Professor, SLT Institute of Pharm. Sciences, Guru Ghasidas University, Bilaspur CG  
India  
Email: [ah\\_bharti@yahoo.com](mailto:ah_bharti@yahoo.com)  
[Home Page](#)



SUDHISH A. RAI  
RJPT House, Lokmanya GrihNirman Society, Rohanipuram, In-front of Sector- 1, Pt. Deendayal  
Upadhyay Nagar, Raipur 492 010. (CG) India  
Email: [sudhishrai7337@gmail.com](mailto:sudhishrai7337@gmail.com)  
[Home Page](#)



DR. ASHOK A. HAJARE  
Professor and Head, Department of Pharm. Tech., Bharati Vidyapeeth College of Pharmacy,  
Kolhapur (M. S.), India Pin - 416013  
Email: [ashok.hajare@bharativedyapeeth.edu](mailto:ashok.hajare@bharativedyapeeth.edu)  
[Home Page](#)



SANYAM GANDHI

International Regulatory Strategy Lead Takeda Pharmaceutical Company Ltd., 1 Kingdon St., Paddinton, London, W2 6BD England  
Email: [askforsanyam@gmail.com](mailto:askforsanyam@gmail.com)  
[Home Page](#)



DR. AJAY KUMAR MEENA

Captain Srinivasa Murthy Regional Ayurveda Drug Development Institute, Arumbakkam, Chennai – 600 106  
Email: [ajaysheera@gmail.com](mailto:ajaysheera@gmail.com)  
[Home Page](#)

## EDITORS

---



DR AVINASH B DAREKAR

KVNNSPS, Institute of Pharmaceutical Education and Research, Canada Corner, Nashik, Maharashtra-422002.  
Email: [avibdarekar@gmail.com](mailto:avibdarekar@gmail.com)  
[Home Page](#)



PRAVEEN KUMAR SHARMA

Department of Chemistry, Lovely Professional University, Phagwara, Punjab, India-144411  
Email: [pk\\_pandit1982@yahoo.com](mailto:pk_pandit1982@yahoo.com)  
[Home Page](#)



DR SUDIP KUMAR MANDAL

Dr. B. C. Roy College of Pharmacy & Allied Health Sciences, Durgapur, West Bengal, India  
Email: [gotosudip79@gmail.com](mailto:gotosudip79@gmail.com)  
[Home Page](#)



DR K MANIKANDAN

Dr.K.Manikandan, M.Pharm., Ph.D., Associate Professor, SRM College of Pharmacy, SRM University, Kattankulathur, Kancheepuram - 603203 Mobile Number - 0 9444708710  
Email: [manikank2@srmist.edu.in](mailto:manikank2@srmist.edu.in)  
[Home Page](#)



DR SHAIK HARUN RASHEED

professor & Head Srikrupa Institute of Pharmaceutical Sciences Velikatta, siddipet -502277  
Telangana.

Email: [shaikharunrasheed@gmail.com](mailto:shaikharunrasheed@gmail.com)

[Home Page](#)



DR. ASHISH KUMAR

Professor and HOD, Department of Chemistry, Lovely Professional University, Jalandhar road  
Phagwara

Email: [drashishchemlpu@gmail.com](mailto:drashishchemlpu@gmail.com)

[Home Page](#)



DR. SHAKTA MANI SATYAM

Department of Pharmacology, Melaka Manipal Medical College (Manipal Campus), Manipal  
Academy of Higher Education, Manipal- 576104, District- Udupi, State- Karnataka (India)

Email: [smsatyam21@gmail.com](mailto:smsatyam21@gmail.com)

[Home Page](#)



ABDULRAHMAN R. MAHMOOD

\*Department of Chemistry, College of Education for Pure Sciences/(Ibn-Al-Haitham), University of  
Baghdad, Baghdad, Iraq.

Email: [abdooljumaily@gmail.com](mailto:abdooljumaily@gmail.com)

[Home Page](#)



DR. SUSHIL KUMAR MIDDHA

Maharani Lakshmi Ammanni College For Women, 18th Cross, Malleswaram, Bangalore-12

Email: [drsushilmiddha@gmail.com](mailto:drsushilmiddha@gmail.com)

[Home Page](#)



MUNIM R. ALI

Al-Mustansiriyah University Biology depart./college of Science Iraq/Baghdad

Email: [mnumbio77@yahoo.com](mailto:mnumbio77@yahoo.com)

[Home Page](#)



DR. GAURAV TIWARI

G-23, Department of Pharmacy, PSIT, NH-2, Kalpi Road, Bhaunti Kanpur 209305

Email: [dr.gauravtiwari@psit.in](mailto:dr.gauravtiwari@psit.in)

[Home Page](#)



DR. ZEYAD KADHIM OLEIWI  
najaf-iraq  
Email: [zeyadkadhim@alkafeel.edu.iq](mailto:zeyadkadhim@alkafeel.edu.iq)  
[Home Page](#)



ASSIST. PROF. DR. AMAL TALIB A  
Dept. Clinical Laboratory Sciences/ Faculty of Pharmacy/ University of Babylon, Iraq.  
Email: [amal.atiyah@yahoo.com](mailto:amal.atiyah@yahoo.com)  
[Home Page](#)



YAHIA MOHAMMAD MOUALLA  
Alsham private university, Latakia  
Email: [Yahiamoualla@hotmail.com](mailto:Yahiamoualla@hotmail.com)  
[Home Page](#)



MOHANAD MOUSA KAREEM  
Babylon University  
Email: [mohanad\\_1972@yahoo.com](mailto:mohanad_1972@yahoo.com)  
[Home Page](#)



ADAWIYA FADHIL ABBAS ALZUBAIDI  
Iraq / Diyala / Baqubah Diyala university / education college / pure science  
Email: [adwa\\_a2000@YAHOO.COM](mailto:adwa_a2000@YAHOO.COM)  
[Home Page](#)



MOUSHIRA ZAKI  
El Bhouth ST.  
Email: [moushiraz@yahoo.com](mailto:moushiraz@yahoo.com)  
[Home Page](#)



DR. AMIT KUMAR CHATURVEDI  
Department Of Chemistry, J.S.University , Shikohabad (U.P.)  
Email: [achaturvedi794@gmail.com](mailto:achaturvedi794@gmail.com)  
[Home Page](#)



DR. MANOJ KUMAR JENA

Department of Biotechnology, School of Bioengineering and Biosciences, Lovely Professional University, Phagwara-144411, Punjab, India

Email: [manoj.20283@lpu.co.in](mailto:manoj.20283@lpu.co.in)

[Home Page](#)



AVINASH BABURAO THALKARI

Vasant Pharmacy College Kaij Affiliated by MSBTE Mumbai

Email: [avinashthalkari@rediffmail.com](mailto:avinashthalkari@rediffmail.com)

[Home Page](#)



RAJESH L. DUMPALA

Alembic Pharma Campus, Alembic Rd, Subhanpura, Vadodara, Gujarat 390003

Email: [rdumpala64@gmail.com](mailto:rdumpala64@gmail.com)

[Home Page](#)



ABDULRAHMAN R. MAHMOOD

\*Department of Chemistry, College of Education for Pure Sciences/(Ibn-Al-Haitham), University of Baghdad, Baghdad, Iraq.

Email: [abdulrahman.r.m@ihcoedu.uobaghdad.edu.iq](mailto:abdulrahman.r.m@ihcoedu.uobaghdad.edu.iq)

[Home Page](#)



DR. T.C. VENKATESWARULU

Department of Bio-Technology, Vignan's Foundation for Science, Technology & Research, Vadlamudi-522213, Andhra Pradesh

Email: [venki\\_biotech327@yahoo.com](mailto:venki_biotech327@yahoo.com)

[Home Page](#)



DR PRASHANT L. PINGALE

Associate Professor of Pharmaceutics, GES's Sir Dr. M. S. Gosavi College of Pharmaceutical Education and Research, Nashik-422005, Maharashtra, India

Email: [prashantpingale@gmail.com](mailto:prashantpingale@gmail.com)

[Home Page](#)



DR GURVINDER SINGH

School of Pharmaceutical Sciences, Lovely Professional University, Phagwara, Punjab

Email: [guri\\_ph@yahoo.co.in](mailto:guri_ph@yahoo.co.in)

[Home Page](#)



DR.SUSHANT KUMAR

UTTAR PRADESH UNIVERSITY OF MEDICAL SCIENCES, SAIFAI, ETWAH, UTTAR PRADESH

Email: [K.SUSHANT25@GMAIL.COM](mailto:K.SUSHANT25@GMAIL.COM)

[Home Page](#)



MR. PARESH ASHOK PATIL

Jay ambe Nivas,Gujar galli, Shahada Dist-Nandurbar

Email: [rcp.pareshpatil@gmail.com](mailto:rcp.pareshpatil@gmail.com)

[Home Page](#)



VAMSIKRISHAN BIRUPANENI

4401 manchester avenue, Apt#53,CA,95207.

Email: [vamsikrishan99@gmail.com](mailto:vamsikrishan99@gmail.com)

[Home Page](#)



DR. SUNIL KUMAR

122 Ground Floor Research Block A Post Graduate Institute of Medical education and Research

Email: [drsunikumarjaswal@gmail.com](mailto:drsunikumarjaswal@gmail.com)

[Home Page](#)



SANDEEP PODDAR

Lincoln University College, Wisma Lincoln, No. 12-18, Off Jalan Perbandaran, SS6/12 Kelana Jaya, Selangor D. E. , Malaysia

Email: [sandeepoddar@lincoln.edu.my](mailto:sandeepoddar@lincoln.edu.my)

[Home Page](#)



DR ZAKIR HUSSAIN

Dr Zakir hussain S/o MD.UNUS Rtd Express mail guard SCRLY Near mohammadia masjid, Satyanarayana pet GUNTAKAL-515801 ANANTAPUR DIST ANDHRA PRADESH-INDIA

Email: [zakirhussains765@gmail.com](mailto:zakirhussains765@gmail.com)

[Home Page](#)



BASIL A. ABBAS

University of Basrah, Basrah, Iraq

Email: [basil.abbas@uobasrah.edu.iq](mailto:basil.abbas@uobasrah.edu.iq)

[Home Page](#)



DR V. PALANISINGH

Puduvadi, Ulagampatti post Sivagangai Dist, Tamil Nadu PIN 630410  
Email: [vpalanisingh@gmail.com](mailto:vpalanisingh@gmail.com)  
[Home Page](#)



NASIR MUWFAQ YOUNIS

University of Mosul \_College of Nursing  
Email: [nasir.mufaq@uomosul.edu.iq](mailto:nasir.mufaq@uomosul.edu.iq)  
[Home Page](#)



SANDIP SEN

SRIKRUPPA INSITUTE OF PHARMACEUTICAL SCIENCES, VELIKATTA, KONDAPKKA,  
SIDDIPET-502277  
Email: [sandipsen2010@gmail.com](mailto:sandipsen2010@gmail.com)  
[Home Page](#)



DR. BISWA MOHAN SAHOO

Roland Institute of Pharmaceutical Sciences (Biju Patnaik University of Technology Nodal Centre  
of Research) Berhampur-760010, Odisha, India  
Email: [drbiswamohansahoo@gmail.com](mailto:drbiswamohansahoo@gmail.com)  
[Home Page](#)



DR.MATADEEN BHARTI

Department of Fluorosis Chief Medical and Health Office Dhar District Dhar MP India pin code  
454001  
Email: [drmdbharti@gmail.com](mailto:drmdbharti@gmail.com)  
[Home Page](#)



DR PRASENJIT MONDAL

Vaageswari institute of Pharmaceutical Sciences, Ramakrishna colony, Karimnagar, Telangana,  
India  
Email: [prasenjitmyname@gmail.com](mailto:prasenjitmyname@gmail.com)  
[Home Page](#)



DR ANJU THAWARE

Associate professor, Dept of samhita Siddhant ,MGACRCH,salod wardha ,(DMIMSU,wardha)  
Maharashtra ,India  
Email: [anju.samhita@dmimsu.edu.in](mailto:anju.samhita@dmimsu.edu.in)

[Home Page](#)



DR. NITIN SHARMA

Department of Biotechnology Chandigarh Group of Colleges, Landran, Mohali- 140307

Email: [nitin.3994@cgc.edu.in](mailto:nitin.3994@cgc.edu.in)

[Home Page](#)



PROF. GALLA RAJITHA

Prof. G. Rajitha, Professor, Institute of Pharmaceutical Technology, Sri Padmavati Mahila Visvavidyalayam, Tirupati - 517502, Andhra Pradesh, India

Email: [rajitha.galla@gmail.com](mailto:rajitha.galla@gmail.com)

[Home Page](#)



ASHISH GUPTA

Flat no.E113,Nariman Point, Mahalaxmi Nagar Indore MP

Email: [ashishgupta@acropolis.edu.in](mailto:ashishgupta@acropolis.edu.in)

[Home Page](#)



HUSAM AL-HRAISHAWI

195 Little Albany St,

Email: [hra10@scarletmail.rutgers.edu](mailto:hra10@scarletmail.rutgers.edu)

[Home Page](#)



TUHIN SARKAR

Jakir Hossain Institute of Pharmacy, Vill. & P.O.- Miapur, Dist.- Murshidabad, Pin: 742225, West Bengal.

Email: [gantuhin@gmail.com](mailto:gantuhin@gmail.com)

[Home Page](#)



BHUPENDRA G. PRAJAPATI

Ganpat Vidyanagar, Mahesna 384012

Email: [bhupen27@gmail.com](mailto:bhupen27@gmail.com)

[Home Page](#)

DR K RAJYALAKSHMI

Department of Pharmaceutical Chemistry, Vignan Pharmacy College, Vadlamudi, Guntur, A.P.





Email: [drkrl3579@gmail.com](mailto:drkrl3579@gmail.com)  
[Home Page](#)



SOURAVH BAIS  
474 VIP PARASPAR NAGAR  
Email: [souravh2008.123@rediffmail.com](mailto:souravh2008.123@rediffmail.com)  
[Home Page](#)



DR. D.S.JAYALAKSHMI  
Sathyabama Institute of Science and Technology (deemed to be University), Rajiv Gandhi Salai,  
OMR  
Email: [jayaanand10@gmail.com](mailto:jayaanand10@gmail.com)  
[Home Page](#)



DR. PARTHA NIYOGI  
SCHOOL OF PHARMACY THE NEOTIA UNIVERSITY SARISHA, DIAMOND HARBOUR WEST  
BENGAL- 743 368  
Email: [partha.niyogi@tnu.in](mailto:partha.niyogi@tnu.in)  
[Home Page](#)



DR. RAJIV DUTTA  
Shobhit Institute of Engineering & Technology (Deemed-to-be-University) NH-58, Modipuram  
Meerut, UP-250110. India  
Email: [director.sbt@gmail.com](mailto:director.sbt@gmail.com)  
[Home Page](#)



PRAVEEN KUMAR UPPALA  
LIG 163 Alakananda colony, Vizianagaram, Andhra Pradesh  
Email: [praveen.chintu32@gmail.com](mailto:praveen.chintu32@gmail.com)  
[Home Page](#)



RAMAKRISHNA REDDY H  
#32, Shiva shakti, 4th Cross, KBL Elite layout, J.P.Nagar 8th Phase, Bangalore-560108,  
Karnataka state, India.  
Email: [rkreddy\\_h@yahoo.co.in](mailto:rkreddy_h@yahoo.co.in)  
[Home Page](#)



DR. PRAVIN KUMAR SHARMA

Acropolis Institute of Pharmaceutical Education and Research, Indore

Email: [praveensharma910@gmail.com](mailto:praveensharma910@gmail.com)

[Home Page](#)



DR. FORAT YASIR ALJABERI

Chemical Engineering Department, College of Engineering, Al-Muthanna University, Samawa, Iraq

Email: [furatyasir@mu.edu.iq](mailto:furatyasir@mu.edu.iq)

[Home Page](#)



DR. L. NANDHAKUMAR

Kastooribha Gandhi Pharmacy college Namakkal, Rasipuram

Email: [drndkumar12@gmail.com](mailto:drndkumar12@gmail.com)

[Home Page](#)



PROF. DR. RAJIV DUTTA

SHOBHIT UNIVERSITY, GANGOH

Email: [director.sbt@gmail.com](mailto:director.sbt@gmail.com)

[Home Page](#)



AHMED ALI MHAWESH

Baghdad/Iraq Al-Ghadeer Quarter

Email: [alshammariahmed.a.m@gmail.com](mailto:alshammariahmed.a.m@gmail.com)

[Home Page](#)



DR JAGDISH KAKADIYA

Department of Pharmacology, Parul Institute of Pharmacy and Research, Parul University, Vadodara, Gujarat, India

Email: [jagdishkakadiya@gmail.com](mailto:jagdishkakadiya@gmail.com)

[Home Page](#)



MAJIDA HAMEED KHAZAAL

Kufa University

Email: [majdahamed69@yahoo.com](mailto:majdahamed69@yahoo.com)

[Home Page](#)



DR. SHOBHIT KUMAR

Dr. Shobhit Kumar, Associate Professor, Department of Pharmaceutical Technology, Meerut Institute of Engineering and Technology (MIET), NH-58, Delhi-Roorkee Highway, Meerut-250005, Uttar Pradesh, India. Tel: +91 9675598375 E-mail: shobhitkmr87@gmail.com  
shobhit.kumar@miet.ac.in  
Email: [shobhit.kumar@miet.ac.in](mailto:shobhit.kumar@miet.ac.in)  
[Home Page](#)



DR. P. DWARAKANADHA REDDY

Annamacharya College of Pharmacy, Rajampet-516126, Andhra Pradesh, India  
Email: [dwarakanadhareddyperam@gmail.com](mailto:dwarakanadhareddyperam@gmail.com)  
[Home Page](#)



PROF. MATOLE VINOD KALIDAS

Shivai Charitable trust's College of Pharmacy, Koregaonwadi Tal. Omerga Dist. Dharashiv Maharashtra India  
Email: [matole7414@gmail.com](mailto:matole7414@gmail.com)  
[Home Page](#)



SANKARGANESH

3/478, Ajith nagar, Sathankuppam, Kelambakkam-603103, Chennai, TN  
Email: [bilisankar@gmail.com](mailto:bilisankar@gmail.com)  
[Home Page](#)



ALAA HUSSEIN AL-DARRAJI

Iraq-Misan  
Email: [alaa.hussein@uomisan.edu.iq](mailto:alaa.hussein@uomisan.edu.iq)  
[Home Page](#)



MANISH KUMAR

SD College, Barnala-148101, Punjab, India.  
Email: [manish@sdcollegeinstitutions.org](mailto:manish@sdcollegeinstitutions.org)  
[Home Page](#)



DR. DINANATH TUKARAM GAIKWAD

223, Shamrao Kumbhar Nagar, Nanapatil Nagar, Kolhapur, Maharashtra, India  
Email: [gddinanath@gmail.com](mailto:gddinanath@gmail.com)  
[Home Page](#)



BEHZAD FOROUTAN

Department of Pharmacology School of Medicine Shahroud University of Medical Sciences

Shahroud, IRAN

Email: [behzad\\_foroutan@hotmail.com](mailto:behzad_foroutan@hotmail.com)

[Home Page](#)



DR. AMIT ROY

Principal, Columbia Institute of Pharmacy, Raipur CG India

Email: [wakratund@gmail.com](mailto:wakratund@gmail.com)

[Home Page](#)



P. PARTHIBAN

Centre for R&D, PRIST University, Thanjavur-613403, India

Email: [parthisivam@yahoo.co.in](mailto:parthisivam@yahoo.co.in)

[Home Page](#)



PROF. D. K. TRIPATHI

Principal, Rungta Institute of Pharmaceutical Sci. and Research, Bhilai CG India

Email: [editor.rjpt@gmail.com](mailto:editor.rjpt@gmail.com)

[Home Page](#)



DR. P. KUMARAVEL

Assistant Professor, Department of Biotechnology, Vysya College, Masinaickenpatty, Salem-636103. Tamil Nadu, India.

Email: [kumaravelbiotech@gmail.com](mailto:kumaravelbiotech@gmail.com)

[Home Page](#)



DR GIRISH PAI K

Faculty - Dept of Pharmaceutics Manipal college of pharmaceutical sciences Manipal University, Madhav Nagar Manipal - 576104, Karnataka State, India

Email: [girish.pai@manipal.edu](mailto:girish.pai@manipal.edu)

[Home Page](#)



DR. AJAY V. PATHAK

House No.33 Ravindra nagar Nagpur-440022 Maharashtra, INDIA

Email: [a.pathak4@gmail.com](mailto:a.pathak4@gmail.com)

[Home Page](#)



AYUSH DOGRA

department of electronics and communications, panjab university chandigarh

Email: [ayush123456789@gmail.com](mailto:ayush123456789@gmail.com)

[Home Page](#)



DR. PRATIBHA VYAS

Department of Microbiology, College of Basic Sciences and Humanities, Punjab Agricultural University, Ludhiana-141004, Punjab, India.

Email: [pratibha.19064@pu.co.in](mailto:pratibha.19064@pu.co.in)

[Home Page](#)



IHSAN HABIB DAKHIL

Engineering College, Al-Muthanna University, Iraq

Email: [ihsanelshahiri@yahoo.com](mailto:ihsanelshahiri@yahoo.com)

[Home Page](#)



DR. JAYASSHREE SEN

J.N.M.C.&A.V.B.R.H., Sawangi, Wardha, Maharashtra 442007

Email: [jayashree\\_sen@rediffmail.com](mailto:jayashree_sen@rediffmail.com)

[Home Page](#)



IMAD

University of Babylon

Email: [imad\\_dna@yahoo.com](mailto:imad_dna@yahoo.com)

[Home Page](#)



RIM M. HARFOUCH

Al Andalus university, Qadmus, Tartous, Syria

Email: [rimharfouch@au.edu.sy](mailto:rimharfouch@au.edu.sy)

[Home Page](#)



MOHAMMAD JAWAD AL-JASSANI

Department of Microbiology, College of Science, Al-Karkh University of Science, Iraq.

Email: [pcr2000@yahoo.com](mailto:pcr2000@yahoo.com)

[Home Page](#)

## REVIEWERS

---



DR. SUBHASHIS DEBNATH

Seven Hills College of Pharmacy Venkatramapuram, Tirupati- 517561

Email: [subhashis.ooty@gmail.com](mailto:subhashis.ooty@gmail.com)

[Home Page](#)



GAURAV KUMAR

Department of Microbiology School of Bioengineering and Biosciences Lovely Professional University Phagwara, 144411, Punjab, India

Email: [gau\\_ravkr@yahoo.com](mailto:gau_ravkr@yahoo.com)

[Home Page](#)



RUCHI VERMA

manipal college of pharmaceutical sciences, manipal university, karnataka, India.

Email: [ruchi.verma@manipal.edu](mailto:ruchi.verma@manipal.edu)

[Home Page](#)



DR. KETAN VINODLAL SHAH

201, Rudrax Appartment, Guruprasad Society, Nehind Telephone exchange, Krishnanagar Main road, Rajkot

Email: [ketan421981@gmail.com](mailto:ketan421981@gmail.com)

[Home Page](#)



K SUJANA

university college of pharmaceutical sciences Acharya Nagarjuna university

Email: [sujana\\_36@yahoo.co.in](mailto:sujana_36@yahoo.co.in)

[Home Page](#)



DR.P.BRINDHA DEVI

Vels University, Velan Nagar, PV Vaithiyalingam Road, Pallavaram

Email: [pbrindhadevi@gmail.com](mailto:pbrindhadevi@gmail.com)

[Home Page](#)



DR VAMSHI KRISHNA TIPPAVAJHALA

Assistant Professor-Senior Scale Department of Pharmaceutics Manipal College of  
Pharmaceutical Sciences Manipal University Manipal, Karnataka, India

Email: [krissrcm@gmail.com](mailto:krissrcm@gmail.com)

[Home Page](#)



ZAIN BAAITY

Syria, Latakia

Email: [zein\\_syria@hotmail.com](mailto:zein_syria@hotmail.com)

[Home Page](#)



LAITH AHMED NAJAM

Mosul University, College of Science, Physics Dept., Mosul

Email: [Prof.lai2014@gmail.com](mailto:Prof.lai2014@gmail.com)

[Home Page](#)



VEEREN DEWOOLKAR

4824 Washtenaw Ave, Apt C1, Ann Arbor, MI 48108

Email: [veerenrx@gmail.com](mailto:veerenrx@gmail.com)

[Home Page](#)



NEERAN OBIED JASIM

University of AL-Qadisiyah college of Pharmacy Iraq

Email: [neran.jasim@qu.edu.iq](mailto:neran.jasim@qu.edu.iq)

[Home Page](#)



MAHMOUD NAJIM ABID

Mustansiriyah University, College of Science, Department of Chemistry

Email: [mahmoudaljibouri@gmail.com](mailto:mahmoudaljibouri@gmail.com)

[Home Page](#)



NILESH PATEL

B/103,Snehkunj Elegance,Behind Shivalay Parisar Kudasan,Gandhinagar-382421,Gujarat

Email: [nilesh33.emcure@gmail.com](mailto:nilesh33.emcure@gmail.com)

[Home Page](#)



NEERAN OBIED JASIM

university of AL-Qadisiyah -college of science-Iraq

Email: [neran.jasim@qu.edu.iq](mailto:neran.jasim@qu.edu.iq)

[Home Page](#)



MARWAN MAHMOOD SALEH

Anbar-Ramadi- Habbaniya- 4-4-17

Email: [ah.marwan\\_bio@uoanbar.edu.iq](mailto:ah.marwan_bio@uoanbar.edu.iq)

[Home Page](#)



PALLAVI LAXMAN PHALKE

Parul University, Limda, Waghodiya. Vadodara-391760, Gujarat India.

Email: [falkepallavi@gmail.com](mailto:falkepallavi@gmail.com)

[Home Page](#)



DR. ANUP S. HENDRE

Biochemistry Department Krishna Institute of Medical Sciences, Malkapur Karad. Dist-Satara.

Email: [anupviews@gmail.com](mailto:anupviews@gmail.com)

[Home Page](#)



SURENDRA KUMAR GAUTAM

Kamla Nehru Institute of Management & Technology, NH96 Faizabad Bypass Road Faridipur Campus

Email: [surendra\\_bkt95@yahoo.in](mailto:surendra_bkt95@yahoo.in)

[Home Page](#)



DR U R RAKSHITH

Dr U R Rakshith Lecturer JSS College of Pharmacy, JSS Academy of Higher Education and Research Shivarathreeswara Nagar, Mysuru-570015 Karnataka , India

Email: [urakshith@jssuni.edu.in](mailto:urakshith@jssuni.edu.in)

[Home Page](#)



RAMU SAMINENI

H.N0-1-123-A; C/O SIVARAMAKRISHNA SAMINENI MANDEPUDI, AMARAVATHI

Email: [samineni.ramu@gmail.com](mailto:samineni.ramu@gmail.com)

[Home Page](#)





DHAVAL PATEL

A-104, Maruti Aamrakunj, Sargasan, Gandhinagar-382421

Email: [dhaval.nine@gmail.com](mailto:dhaval.nine@gmail.com)

[Home Page](#)



AKHIL NAGAR

R C PATEL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH

Email: [akkipharma23@gmail.com](mailto:akkipharma23@gmail.com)

[Home Page](#)



SUNANDAR IHSAN

Kampus Hijau Bumi Tridharma Universitas Halu Oleo Fakultas Farmasi, Jl. H.E.A Mokodompit Anduonuhu, Kendari, Indonesia

Email: [sunandarihsan@uho.ac.id](mailto:sunandarihsan@uho.ac.id)

[Home Page](#)



ANAS TARIK NAFEI

Baghdad, Qadissiyah Express way

Email: [anasalhamdany@yahoo.com](mailto:anasalhamdany@yahoo.com)

[Home Page](#)



DR.KUMARASWAMY GULLAPELLI

STREET NUMBER 4 , BHAVANI NAGAR , NACHARAM, HYDERABAD NACHARAM, Hyderabad, Telangana, pincode: 500076

Email: [kumargullapelli001@gmail.com](mailto:kumargullapelli001@gmail.com)

[Home Page](#)



RADHWAN AL-ZIDAN

Almothana district, Mosul, Iraq

Email: [radhwan.alzidan@uomosul.edu.iq](mailto:radhwan.alzidan@uomosul.edu.iq)

[Home Page](#)



YAHIA M. MOUALLA

faculty of pharmacy, Tishreen university, Latakia, Syria

Email: [yahia.moualla@tishreen.edu.sy](mailto:yahia.moualla@tishreen.edu.sy)

[Home Page](#)



SUHAS SURESH AWATI

Assistant Professor, Dr. Shivajirao Kadam College of Pharmacy, Kasabe Digraj, Baganvat, Tal-Miraj, Dist- Sangli, Maharashtra. 416301

Email: [awatiss@gmail.com](mailto:awatiss@gmail.com)

[Home Page](#)



SHAIK FIROZ

Assistant Professor, Department of Pharmaceutics, Sree Vidyanikethan College of Pharmacy, Sree Sainath Nagar, A.Rangampet-517102.

Email: [firoz.kallur@gmail.com](mailto:firoz.kallur@gmail.com)

[Home Page](#)



DR NASEEF PP

Vice Principal, Moulana College of Pharmacy, Near Angadippuram Railway Station, Malappuram, Kerala, India 679321

Email: [drnaseefpp@gmail.com](mailto:drnaseefpp@gmail.com)

[Home Page](#)



DR. ARINDAM CHATTERJEE

School of Pharmaceutical Sciences Jaipur National University (SADTM Campus) Near RTO Office, Jaipur Agra Bypass Jagatpura, Jaipur, Rajasthan India-302017

Email: [chatterjee.arindam@hotmail.com](mailto:chatterjee.arindam@hotmail.com)

[Home Page](#)



S RAJARAJAN

Department of Pharmaceutics, Karnataka College of Pharmacy 33/2, Thirumena Halli, Hegde Nagar Main Road, Bangalore-560064

Email: [pharmking@gmail.com](mailto:pharmking@gmail.com)

[Home Page](#)



DR . RAHUL RADHAKRISHNAN

Manasam, Edavattom, Chirakkara (PO) ,Kollam, Kerala

Email: [drrahulpharmd@gmail.com](mailto:drrahulpharmd@gmail.com)

[Home Page](#)



RIM M. HARFOUCH

0624 Albaath street, Latakia, Syria

Email: [rimharf@yahoo.com](mailto:rimharf@yahoo.com)

[Home Page](#)



ARUN A

3/31 periyar street, ramapuram chennai 600089  
Email: [arunarticle2016@gmail.com](mailto:arunarticle2016@gmail.com)  
[Home Page](#)



ABDUL SALEEM MOHAMMAD

Department of Pharmaceutical Analysis and Quality Assurance, Nizam Institute of Pharmacy, Deshmukhi (V), Pochampally (M), Behind Mount Opera, Nalgonda (Dist)-508284, Telangana, India.  
Email: [mohdsaleempharma@gmail.com](mailto:mohdsaleempharma@gmail.com)  
[Home Page](#)



KARTHIKEYAN T

registrar nimhans  
Email: [karthik\\_77in@yahoo.co.in](mailto:karthik_77in@yahoo.co.in)  
[Home Page](#)



DR. PUTTA RAJESH KUMAR

Amdapur X Road, Yenkapally, Moinabad, Ranga Reddy, Hyderabad, Telangana 500075 INDIA  
Email: [prkbpc@gmail.com](mailto:prkbpc@gmail.com)  
[Home Page](#)



AAMINAH NAJMUS SAHAR

H.no: 121, Pension lane, New Bowenpally Secunderabad- 500011  
Email: [aaminahnajmus@yahoo.in](mailto:aaminahnajmus@yahoo.in)  
[Home Page](#)



ZAINAB HAITHAM FATHI

College of Pharmacy, University of Mosul  
Email: [zainabh@uomosul.edu.iq](mailto:zainabh@uomosul.edu.iq)  
[Home Page](#)



DR. OM PRAKASH RANJAN

Faculty of Pharmacy, Sachchidanad Sinha College, Aurangabad, Bihar.  
Email: [omprakasranjan@gmail.com](mailto:omprakasranjan@gmail.com)  
[Home Page](#)



SHASHIKANT SUDARSHAN UPADHYE

Annasaheb Dange College of B.Pharmacy, Ashta Tal: Walwa, Dist: Sangli 416301 , Maharashtra, India

Email: [ssupadhye7@gmail.com](mailto:ssupadhye7@gmail.com)

[Home Page](#)



VISHAL KUMAR BISWKARMA

KSCP, Subharti University, Meerut, Uttar Pradesh, India

Email: [vishalkumarbiswkarma@gmail.com](mailto:vishalkumarbiswkarma@gmail.com)

[Home Page](#)



DR. C. JANANI

Dr. C. Janani, Srimad Andavan Arts and Science College, Nelson Road, TV Kovil, Trichy-05

Email: [janabio.net@gmail.com](mailto:janabio.net@gmail.com)

[Home Page](#)



RANJAN KUMAR SINGH

g d memorial college of pharmacy, kbhb, jodhpur.342005

Email: [rsingh8@gmail.com](mailto:rsingh8@gmail.com)

[Home Page](#)



BIMESH KUMAR

BLOCK 4, ROOM NO 203, SCHOOL OF PHARMACEUTICAL SCIENCES, LOVELY PROFESSIONAL UNIVERSITY, PHAGWARA, PUNJAB, 144411.

Email: [bimlesh1pham@gmail.com](mailto:bimlesh1pham@gmail.com)

[Home Page](#)



DR.BISWARANJAN RAY

Associate prof, Dept. of Pharmacology, College of Pharmaceutical Sciences, Puri, Odisha

Email: [crabiswa@gmail.com](mailto:crabiswa@gmail.com)

[Home Page](#)



ANAR J PATEL

Sal Institute of Pharmacy, Ahmedabad

Email: [anar.patel@sal.edu.in](mailto:anar.patel@sal.edu.in)

[Home Page](#)



GANESH BARKADE

Dr. Vithalrao Vikhe Patil Foundation's College of Pharmacy, Ahmednagar, MH, India-414111 Vikhe Patil Foundation

Email: [ganeshbarkade7@gmail.com](mailto:ganeshbarkade7@gmail.com)

[Home Page](#)



DR. VEDAMURTHY JOSHI

Associate professor, Sri Adichunchanagiri College of Pharmacy, BG Nagara Nagamangala Tq Mandya dist Karnata

Email: [vedamurthyjoshi@gmail.com](mailto:vedamurthyjoshi@gmail.com)

[Home Page](#)



AVINASH BABURAO THALKARI

Kanadi Road Kaij Vasant Pharmacy College Kaij Kanadi Road Kaij

Email: [avinashthalkari@gmail.com](mailto:avinashthalkari@gmail.com)

[Home Page](#)



DR. P. PRAVEEN REDDY

Vivekananda Degree and PG College, Karimnagar-505001, Telangana

Email: [microppr@gmail.com](mailto:microppr@gmail.com)

[Home Page](#)



MUTHUKUMAR.S

45,U.K.Thevar Street, Suler, Coimbatore-641402

Email: [pharmuthu@gmail.com](mailto:pharmuthu@gmail.com)

[Home Page](#)



D CHANDRA SEKHAR NAIK

KVSR Siddhartha college of pharmaceutical sciences poly clinical road Vijayawada-10

Email: [chandu.desavath@gmail.com](mailto:chandu.desavath@gmail.com)

[Home Page](#)



BHARAT MISHRA

Nirmala college of pharmacy, Nirmala Hills, Muvattupuzha, Ernakulam, Kerala, India

Email: [bharatekash@gmail.com](mailto:bharatekash@gmail.com)

[Home Page](#)



MATOLE VINOD KALIDAS  
AT POST AURAD TAL.OMERGA DIST .OSMANABAD  
Email: [vinodmatole57@gmail.com](mailto:vinodmatole57@gmail.com)  
[Home Page](#)



NIRMAL THAKKER  
B-602, Tirupati Aakruti Greenz, Behind Nirma University, S.G. Highway, Ahmedabad-382481,  
Gujarat, India  
Email: [nirmalthakker117@yahoo.com](mailto:nirmalthakker117@yahoo.com)  
[Home Page](#)



JASWANTH GOWDA B.H.  
Yenepoya (Deemed to be University), Deralakatte, Mangalore, India-575018.  
Email: [jaswanth\\_14601@yenepoya.edu.in](mailto:jaswanth_14601@yenepoya.edu.in)  
[Home Page](#)



ZEINA ABDULMUNIM ALTHANOON  
Albaladiyat Quarter Mosul Iraq  
Email: [ph.zeinaalthanoon@gmail.com](mailto:ph.zeinaalthanoon@gmail.com)  
[Home Page](#)



SHIVAVEERAKUMAR  
Department of Microbiology, Davangere University, Davanagere - 577002, Karnataka  
Email: [shiv\\_math1984@rediffmail.com](mailto:shiv_math1984@rediffmail.com)  
[Home Page](#)



DR.V.K.EVANJELENE  
16, Anbu Nagar, gorimedu, Salem - 636 008  
Email: [evankutty@gmail.com](mailto:evankutty@gmail.com)  
[Home Page](#)



ASHISH TALE  
MUPS College of Pharmacy, Degaon, Tq. Risod, Dist. Washim-444506 (M.S) India  
Email: [ashishtale93@gmail.com](mailto:ashishtale93@gmail.com)  
[Home Page](#)



DR. C. JANANI

Srimad Andavan Arts and Science College, Nelson Road, TV Kovil TV kovil  
Email: [janabio.net@gmail.com](mailto:janabio.net@gmail.com)  
[Home Page](#)



PRATHEEP THANGARAJ

Department of Biotechnology, PRIST Deemed to be University, Thanjavur-613403, India.  
Email: [pratheetp@gmail.com](mailto:pratheetp@gmail.com)  
[Home Page](#)



SHAIMAA AHMAD HASSAN

AlKarkh University of science / Baghdad / Iraq  
Email: [dr.shaimaa\\_altaee@kus.edu.iq](mailto:dr.shaimaa_altaee@kus.edu.iq)  
[Home Page](#)



DR ANUP NAHA

Manipal College of Pharmaceutical Sciences, MAHE, Manipal, Karnataka-576104  
Email: [anupnaha@gmail.com](mailto:anupnaha@gmail.com)  
[Home Page](#)



EIMAN SHAHROUR

lattakia- syria  
Email: [eimanm.shahrour@gmail.com](mailto:eimanm.shahrour@gmail.com)  
[Home Page](#)



DR. DEVAKUMAR DINESH

Department of Zoology, Bharathiar University Coimbatore-641046 Tamilnadu India  
Email: [devadinesh4041@gmail.com](mailto:devadinesh4041@gmail.com)  
[Home Page](#)



AUDUMBAR DIGAMBAR MALI

At. Po. Andhalgaon, Tal-mangalwedha, Dist- Solapur, Pin Code:- 413305, Maharashtra, India.  
Email: [maliaudu442@gmail.com](mailto:maliaudu442@gmail.com)  
[Home Page](#)



DR. MITTAL MAHESHWARI  
A- One Pharmacy College, Ahmedabad  
Email: [mittalmaheshwary@gmail.com](mailto:mittalmaheshwary@gmail.com)  
[Home Page](#)



ABDUL AZEEM  
Research Scholar, Electrical Engineering Department Jamia Millia Islamia-New Delhi  
Email: [azeemnith@gmail.com](mailto:azeemnith@gmail.com)  
[Home Page](#)



DR. V. VADIVEL  
PG & Research Department of Botany, V.O. Chidambaram College, Tuticorin - 628008 Tamil Nadu, India  
Email: [drvvadivel@gmail.com](mailto:drvvadivel@gmail.com)  
[Home Page](#)



PROF.(DR.) KUMARASWAMY.GANDLA  
Dr.Kumara Swamy.Gandla Associate Editor of RJPT (Research journal of Pharmacy and Technology Chaitanya Deemed to be University, Hanamkonda, Warangal-Urban (Dist), Telangana 506001-India. Mobile: +91-9000973789 / +91-7801022789  
Email: [drkumaraswamygandla@gmail.com](mailto:drkumaraswamygandla@gmail.com)  
[Home Page](#)



MR. PATIL AMOL MANIK  
AT/P- KASEGAON TAL- WALWA DIST- SANGLI PIN CODE- 415404 MAHARASHTRA  
Email: [amp6389@gmail.com](mailto:amp6389@gmail.com)  
[Home Page](#)



MOH MIRZA NURYADY  
Blok HC No. 14, Jl. Intan 2, Perum GPA, Ngijo, Kec. Karangploso, Kabupaten Malang, East Java  
Email: [mirzanuryady@umm.ac.id](mailto:mirzanuryady@umm.ac.id)  
[Home Page](#)



SHAIMAA AHMAD HASSAN  
College of Remote Sensing & Geophysics, Al Karkh University of Science, Baghdad, Iraq  
Email: [dr.shaimaa\\_altaee@kus.edu.iq](mailto:dr.shaimaa_altaee@kus.edu.iq)  
[Home Page](#)





MAUSAMI VAGHELA

New College Wadi-3, B/H Punjab Honda, Opp. sitvan Flat, Kalawad Road, Rajkot.

Email: [mausami\\_2123@yahoo.com](mailto:mausami_2123@yahoo.com)

[Home Page](#)



KOTESHWARA MUDIGONDA

Suven Life Sciences Limited, Hyderabad, India

Email: [koteswara\\_mudigonda@yahoo.com](mailto:koteswara_mudigonda@yahoo.com)

[Home Page](#)



DR. SWAMY C T

51, Anna Arch Rd,NSK Nagar, Anna Nagar, AA Hospital Campus

Email: [swamyc23@gmail.com](mailto:swamyc23@gmail.com)

[Home Page](#)



KHUDHAIR ABBAS KAREEM AL-RUDAI

Iraq, Baghdad

Email: [khudhair.2010@yahoo.com](mailto:khudhair.2010@yahoo.com)

[Home Page](#)



BALJEET YADAV

1202 H, Coralwood Sector 84, Gurugram INDIA

Email: [baljeet.yadav@gdgu.org](mailto:baljeet.yadav@gdgu.org)

[Home Page](#)



DR NILIMA ABHIJEET THOMBRE

MET's Institute Of Pharmacy, Bhujbal Knowledge City, Adgaon, Nasik-422003, Maharashtra,India.

[nilimat\\_iop@bkc.met.edu](mailto:nilimat_iop@bkc.met.edu) 09422284082 , 09960646693

Email: [nilimat\\_iop@bkc.met.edu](mailto:nilimat_iop@bkc.met.edu)

[Home Page](#)



SNIGDHO DAS

Flat No.6,Ira Appartments-2,Jadunath Ukil Road, Kudghat

Email: [snigdho1991@gmail.com](mailto:snigdho1991@gmail.com)

[Home Page](#)



DR SUDARSAN BISWAL

O/o the Asst. Drugs Controller, Bhubaneswar Circle II, Bhubaneswar, Khordha, Odisha, India

Email: [drsbiswaldi@gmail.com](mailto:drsbiswaldi@gmail.com)

[Home Page](#)



NAZIYA IQBAL KHAN

38 Sahyadri nagar Isbavi Pandharpur 413307 Solapur Maharashtra

Email: [naziya.aara@gmail.com](mailto:naziya.aara@gmail.com)

[Home Page](#)



DR GYANENDRA KUMAR SHARMA

Anand College of Pharmacy, Agra

Email: [gyanendrasharma.acp@sgei.org](mailto:gyanendrasharma.acp@sgei.org)

[Home Page](#)



MISS.MALI SUNAYANA MALLAPPA

A/P-Andhalgaon, Pin No. -413 305 Tal- Mangalwedha, Dist-Solapur, Maharashtra, India

Email: [sunayanamali01@gmail.com](mailto:sunayanamali01@gmail.com)

[Home Page](#)



DR. ARUNACHALAM MUTHURAMAN

Dr. Arunachalam Muthuraman, M. Pharm., Ph.D. Associate Professor, Pharmacology Unit, Faculty of Pharmacy, AIMST University, Semeling, 08100 Bedong, Kedah Darul Aman, Malaysia.

E-mail: [arunachalammu@gmail.com](mailto:arunachalammu@gmail.com) Phone No: +60-1136293386 (Malaysia); +91-9988040886

(India) Malaysia Office: +60-44298000 (Extn: 1281 / 1284);

Email: [arunachalammu@gmail.com](mailto:arunachalammu@gmail.com)

[Home Page](#)



MUKUL SHARMA

Faculty of Pharmacy, Medi-Caps University, Indore

Email: [mukul.sharma@medicaps.ac.in](mailto:mukul.sharma@medicaps.ac.in)

[Home Page](#)



PROF. DR. NAGHAM MAHMOOD ALJAM

Professor , Department of Chemistry , Synthetic Field, Iraq.

Email: [dr.nagham\\_mj@yahoo.com](mailto:dr.nagham_mj@yahoo.com)

[Home Page](#)



PRASHANT PANDEY

Department of Pharmaceutical Sciences, Babasaheb Bhimrao Ambedkar University, Lucknow

Email: [mrpandeyprashant@gmail.com](mailto:mrpandeyprashant@gmail.com)

[Home Page](#)



PATHAN HUJEB AFSAR KHAN

Shreeyash Institute of Pharmaceutical Education and Research Aurangabad, Maharashtra, India.

Email: [pathanhujeb@gmail.com](mailto:pathanhujeb@gmail.com)

[Home Page](#)



DR. SHIKHA MAHESHWARI

Pushpanjali Enclave Pitampura Delhi

Email: [shikhamaheshwarimohta@gmail.com](mailto:shikhamaheshwarimohta@gmail.com)

[Home Page](#)



DR V N MEENA DEVI

Noorul Islam Centre for Higher Education Kumaracoil, Kanyakumari Dist. Tamilnadu 629180 India.

Email: [meenadevi@niuniv.com](mailto:meenadevi@niuniv.com)

[Home Page](#)



PRASHANT PANDEY

Department of Pharmaceutical Sciences, Babasaheb Bhimrao Ambedkar University (A Central University), Lucknow, Uttar Pradesh, India

Email: [drpandeyprashant@outlook.com](mailto:drpandeyprashant@outlook.com)

[Home Page](#)



MR. TUSHAR PRADIP DUKRE

At- Malwadi; Post- Bota.

Email: [tusharpd23@gmail.com](mailto:tusharpd23@gmail.com)

[Home Page](#)



DR. DATTATRAYA MANOHAR SHINKA

Rajiv Nagar Nashik Vaibhav Colony

Email: [dattashinkar@gmail.com](mailto:dattashinkar@gmail.com)

[Home Page](#)



PROF. SACHIN NAMDEO KOTHAWADE

Sitabai Thite College of Pharmacy, Pune-Nagar Bypass, Behind Hudco Colony, Shirur, Tal - Shirur, Dist - Pune, Pin - 412210

Email: [sachin.kothawade23@gmail.com](mailto:sachin.kothawade23@gmail.com)

[Home Page](#)



DR.SIVARAMAN DHANASEKARAN

Pandit Deendayal Energy University, Gandhinagar, Gujarat

Email: [sivaramand83@gmail.com](mailto:sivaramand83@gmail.com)

[Home Page](#)



ALI MAHMOOD RAYSHAN

Iraq, Karbala, City Center

Email: [alireshan@g.alzahu.edu.iq](mailto:alireshan@g.alzahu.edu.iq)

[Home Page](#)



DUKRE TUSHAR PRADIP

At- Satral, Post- Songaon, Tal- Rahuri, District-Ahmednagar, 413711

Email: [tusharpd23@gmail.com](mailto:tusharpd23@gmail.com)

[Home Page](#)



DR. SK. ARIFA BEGUM

Dr. Sk. Arifa Begum, Assistant Professor, KVSR Siddhartha College of Pharmaceutical Sciences, Siddhartha Nagar, Vijayawada - 520 010, Andhra Pradesh, India.

Email: [arifashaik2007@gmail.com](mailto:arifashaik2007@gmail.com)

[Home Page](#)



RUPALI NIRMAL

Sahajanandnagar

Email: [rupalinirmalcpn@gmail.com](mailto:rupalinirmalcpn@gmail.com)

[Home Page](#)



RISHU YADAV

352/1 n.l.c. Kidwai Nagar Kanpur

Email: [rishu.yadav789@gmail.com](mailto:rishu.yadav789@gmail.com)

[Home Page](#)



DR. YASMIN HAMID MOMIN

Annasaheb Dange College of B.Pharmacy, Ashta 416301

Email: [mullays413@gmail.com](mailto:mullays413@gmail.com)

[Home Page](#)



PRAVEEN KUMAR UPPALA

LIG 163, Alakananda Colony, Vizianagaram, Andhra Pradesh

Email: [praveen.chintu32@gmail.com](mailto:praveen.chintu32@gmail.com)

[Home Page](#)



DR. EKA INDRA SETYAWAN

Department of Pharmacy Udayana University

Email: [ekaindrasetyawan@unud.ac.id](mailto:ekaindrasetyawan@unud.ac.id)

[Home Page](#)



DR. MOHAN GANDHI BONTHU

V. V. Institute of Pharmaceutical Sciences, Gudlavalleru, Krishna District 521356.

Email: [bmgandhipharma@gmail.com](mailto:bmgandhipharma@gmail.com)

[Home Page](#)



SWATI GOKUL TALELE

Sandip Institute of Pharmaceutical Sciences, Nashik

Email: [swatitalele77@gmail.com](mailto:swatitalele77@gmail.com)

[Home Page](#)

# ARTICLES IN VOLUME - 16, ISSUE - 2

[Online Since: Tuesday, Feb 28, 2023](#) [ [Views: 97050](#) ]

## Hepatocorrective effects of Hydroethanolic Extract of Cocos nucifera L. sprout and Borassus flabellifer Sprout in Carbon tetrachloride (CCl<sub>4</sub>) induced hepatotoxic rats

**Author(s):** P. Sumi, K. Thangavelu, S. Senthil Kumari

**DOI:** [10.52711/0974-360X.2023.00082](https://doi.org/10.52711/0974-360X.2023.00082)

**Views:** 0 (pdf), 1494 (html)

**Access:**  Closed Access

**Cite:** P. Sumi, K. Thangavelu, S. Senthil Kumari. Hepatocorrective effects of Hydroethanolic Extract of Cocos nucifera L. sprout and Borassus flabellifer Sprout in Carbon tetrachloride (CCl<sub>4</sub>) induced hepatotoxic rats. *Research Journal of Pharmacy and Technology* 2023; 16(2):483-8. doi: 10.52711/0974-360X.2023.00082

[Read More](#)

## Isolation of Betulinic Acid from Byttneria herbacea (Malvaceae)

**Author(s):** Sanjeeb K. Kar, Uma S. Mishra, Prasanna K. Dixit, Shubhrata Nayak

**DOI:** [10.52711/0974-360X.2023.00091](https://doi.org/10.52711/0974-360X.2023.00091)

**Views:** 0 (pdf), 1042 (html)

**Access:**  Closed Access

**Cite:** Sanjeeb K. Kar, Uma S. Mishra, Prasanna K. Dixit, Shubhrata Nayak. Isolation of Betulinic Acid from Byttneria herbacea (Malvaceae). *Research Journal of Pharmacy and Technology* 2023; 16(2):535-8. doi: 10.52711/0974-360X.2023.00091

[Read More](#)

## Characterization and Antibacterial Evaluation of New Complexes of Nicotinamide semicarbazone Manganese (II), Zinc (II), Silver (I) Synthesizes

**Author(s):** Amal M. Ali, Heba A. Mohammed, Zeena U. Jasim, Rana R. Abed

**DOI:** [10.52711/0974-360X.2023.00092](https://doi.org/10.52711/0974-360X.2023.00092)

**Views:** 0 (pdf), 1289 (html)

**Access:**  Closed Access

**Cite:** Amal M. Ali, Heba A. Mohammed, Zeena U. Jasim, Rana R. Abed. Characterization and Antibacterial Evaluation of New Complexes of Nicotinamide semicarbazone Manganese (II), Zinc (II), Silver (I) Synthesizes. *Research Journal of Pharmacy and Technology* 2023; 16(2):539-4. doi: 10.52711/0974-360X.2023.00092

[Read More](#)

## HS-GC Method Development and Validation for the Estimation of Class-2 Residual Solvents in Ivabradine

**Author(s):** A. Lakshmi Sai Durga, B. Ramya Kuber

**DOI:** [10.52711/0974-360X.2023.00093](https://doi.org/10.52711/0974-360X.2023.00093)

**Views:** 0 (pdf), 920 (html)

**Access:**  Closed Access

**Cite:** A. Lakshmi Sai Durga, B. Ramya Kuber. HS-GC Method Development and Validation for the Estimation of Class-2 Residual Solvents in Ivabradine. *Research Journal of Pharmacy and Technology* 2023; 16(2):545-9. doi: 10.52711/0974-360X.2023.00093

[Read More](#)

[Read More](#)

## The Effect of Jackfruit (*Artocarpus heterophyllus* Lam.) Seed Ethanol Extract on Blood Sugar Levels and Anti-Inflammatory Reduction on Wistar Albino Rats Streptozotocin-Induced Gestational Diabetes

**Author(s):** Basaria Manurung, Hadyanto Lim, Jekson Martiar Siahaan, Endy Juli Anto, Putri C Eyanoer, Sandeep Poddar

**DOI:** [10.52711/0974-360X.2023.00138](https://doi.org/10.52711/0974-360X.2023.00138)

**Views:** 0 (pdf), 2111 (html)

**Access:**  Closed Access

**Cite:** Basaria Manurung, Hadyanto Lim, Jekson Martiar Siahaan, Endy Juli Anto, Putri C Eyanoer, Sandeep Poddar. The Effect of Jackfruit (*Artocarpus heterophyllus* Lam.) Seed Ethanol Extract on Blood Sugar Levels and Anti-Inflammatory Reduction on Wistar Albino Rats Streptozotocin-Induced Gestational Diabetes. *Research Journal of Pharmacy and Technology* 2023; 16(2):804-8. doi: [10.52711/0974-360X.2023.00138](https://doi.org/10.52711/0974-360X.2023.00138)

[Read More](#)

## Impact of Covid-19 on Mental Health among Medical Students

**Author(s):** U.S. Mahadeva Rao, Thant Zin, Suganya M, Jivaneswaran A/L Kanasan, Afnan Anaqi Bin Afriezul, Siti Hajar Amirah Binti Roslan, Nur Syakirah Bt Che Seman, Maizun Binti Mohamad Ali Khan

**DOI:** [10.52711/0974-360X.2023.00139](https://doi.org/10.52711/0974-360X.2023.00139)

**Views:** 0 (pdf), 1085 (html)

**Access:**  Closed Access

**Cite:** U.S. Mahadeva Rao, Thant Zin, Suganya M, Jivaneswaran A/L Kanasan, Afnan Anaqi Bin Afriezul, Siti Hajar Amirah Binti Roslan, Nur Syakirah Bt Che Seman, Maizun Binti Mohamad Ali Khan. Impact of Covid-19 on Mental Health among Medical Students. *Research Journal of Pharmacy and Technology* 2023; 16(2):809-0. doi: [10.52711/0974-360X.2023.00139](https://doi.org/10.52711/0974-360X.2023.00139)

[Read More](#)

## Correlation between CXCR4 and MMP-2 Expression with T Stage in Clear Cell Renal Cell Carcinoma

**Author(s):** Pamela Kusumadewi Putri Thaib, Anny Setijo Rahaju, Ety Hary Kusumastuti

**DOI:** [10.52711/0974-360X.2023.00140](https://doi.org/10.52711/0974-360X.2023.00140)

**Views:** 0 (pdf), 767 (html)

**Access:**  Closed Access

**Cite:** Pamela Kusumadewi Putri Thaib, Anny Setijo Rahaju, Ety Hary Kusumastuti. Correlation between CXCR4 and MMP-2 Expression with T Stage in Clear Cell Renal Cell Carcinoma. *Research Journal of Pharmacy and Technology* 2023; 16(2):821-9. doi: [10.52711/0974-360X.2023.00140](https://doi.org/10.52711/0974-360X.2023.00140)

[Read More](#)

## Comparison between the Diagnostic Performances of Rapid Diagnostic Test (RDT) using Advantage Malaria Card Pf/Pv Ag, Microscopy, and Polymerase Chain Reaction (PCR) in Malaria Suspected patients at the Merauke Regional General Hospital

**Author(s):** Amarensi Milka Betaubun, Christophorus Oetama Adiatmaja, Trieva V. Butarbutar, Puspa Wardhani, Aryati

**DOI:** [10.52711/0974-360X.2023.00087](https://doi.org/10.52711/0974-360X.2023.00087)

**Views:** 0 (pdf), 1095 (html)

**Access:**  Closed Access

**Cite:** Amarensi Milka Betaubun, Christophorus Oetama Adiatmaja, Trieva V. Butarbutar, Puspa Wardhani, Aryati. Comparison between the Diagnostic Performances of Rapid Diagnostic Test (RDT) using Advantage Malaria Card Pf/Pv Ag, Microscopy, and Polymerase Chain Reaction (PCR) in Malaria Suspected patients at the Merauke Regional General Hospital. *Research Journal of Pharmacy and Technology* 2023; 16(2):514-8. doi: [10.52711/0974-360X.2023.00087](https://doi.org/10.52711/0974-360X.2023.00087)

**RESEARCH ARTICLE**

## Correlation between CXCR4 and MMP-2 Expression with T Stage in Clear Cell Renal Cell Carcinoma

Pamela Kusumadewi Putri Thaib<sup>1,2,3</sup>, Anny Setijo Rahaju<sup>1,2,3\*</sup>, Ety Hary Kusumastuti<sup>1,3</sup>

<sup>1</sup>Department of Anatomical Pathology, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia.

<sup>2</sup>Universitas Airlangga Academic Hospital, Surabaya, Indonesia.

<sup>3</sup>Dr. Soetomo General Academic Hospital, Surabaya, Indonesia.

\*Corresponding Author E-mail: [anny\\_sr@fk.unair.ac.id](mailto:anny_sr@fk.unair.ac.id)

### ABSTRACT:

Clear cell renal cell carcinoma (ccRCC) is the most common type of kidney cancer with high mortality. Escalation of T stage associates with worse survival. Proper and significant biomarker examination necessary to determine the predictive factor and the opportunity of targeted therapy as well. Upregulated CXCR4 expression on cancer cell promotes its aggressive growth, dissemination, metastasis, and conventional therapy resistance. Overexpression of CXCR4 may induce MMP-2 activity on tumor cell, an enzyme that degrade extracellular matrix and basal membrane particularly, which associated with tumor invasion and metastasis. Those biomarkers activity might be advantaged under hypoxic microenvironment in ccRCC. This study aimed to analyze the role and correlation of CXCR4 and MMP-2 expression with various T stages in ccRCC. Analytic observational study with cross-sectional approach was conducted on 43 formalin-fixed paraffin-embedded tissue of patients diagnosed as ccRCC in Anatomical Pathology Laboratory of Dr. Soetomo Hospital throughout January 2015 until December 2020. CXCR4 and MMP-2 expression were evaluated by immunohistochemistry. Statistical analysis with Kruskal-Wallis and Spearman test were utilized to analyze the expression difference and correlation. Difference of both CXCR4 ( $p=0.016$ ) and MMP-2 ( $p=0.029$ ) expression were obtained on various T stages. There was a significant positive correlation between CXCR4 expression ( $p=0.001$ ) and MMP-2 expression ( $p=0.002$ ) with T stage, also between CXCR4 with MMP-2 expression in various T stage of ccRCC ( $p=0.000$ ). In conclusion, this study exhibited that CXCR4 and MMP-2 expression showed synergistic and positive correlation with T stage and might be considered as the basis of targeted therapy in ccRCC.

**KEYWORDS:** Clear cell renal cell carcinoma, CXCR4, MMP-2, T stage, kidney cancer.

### INTRODUCTION:

Renal cell carcinoma is a malignant neoplasm originated from renal epithelial cells and encompasses more than 90% of kidney cancer<sup>1</sup>. This carcinoma comprising more than 10 histology and molecular subtypes, which is clear cell type is the most common type (80%) and has high metastasis propensity to bone, lung, and liver<sup>2,3</sup>. The GLOBOCAN statistic report ranked kidney cancer as the 14<sup>th</sup> most common cancer worldwide, counted for 431.288 new cases in 2020, and the 9<sup>th</sup> most common cancer in male<sup>4</sup>.

Like most of kidney neoplasms, clear cell renal cell carcinoma (ccRCC) is more common in men rather in women with ratio approximately 2:1<sup>3,5</sup>.

The peak age incidence of this malignancy is within 60-70 years<sup>5,6</sup>. A study in Indonesia showed that the incidence of kidney cancer is 2.4-3 cases in 100.000 population<sup>7</sup>.

Morphology characteristic of clear cell renal cell carcinoma is rich in lipid and glycogen content, as well as high vascularity, indicating that altered fatty acid and glucose metabolism is occurred during the development of tumor cells<sup>1,3</sup>. High lipid and glucose content in the cytoplasm of tumor cells will lysis during histopathology process, resulting a clear to mild eosinophilic cytoplasm, thus giving a clear cell appearance<sup>8</sup>. This carcinoma mostly occurred sporadically, only 2-4% cases are hereditary. Inactivation of von Hippel-Lindau (VHL) gene underlying the development of this tumor cells, both in sporadic and hereditary cases<sup>8,9</sup>. Tumor stage is the most important parameter affecting survival in ccRCC,

Received on 15.11.2021

Modified on 19.03.2022

Accepted on 04.06.2022

© RJPT All right reserved

Research J. Pharm. and Tech 2023; 16(2):821-829.

DOI: 10.52711/0974-360X.2023.00140



followed with tumor grade<sup>10,11</sup>. Staging of renal cell carcinoma refers to WHO/8<sup>th</sup> edition of AJCC (American Joint Committee on Cancer) TNM staging system<sup>12</sup>. T stage is generally based on local extension of primary tumor and invasion into the surrounding adjacent tissue, consists of stages T1 to T4<sup>3,11</sup>. An increase of T stage associated with worse survival, recurrency, and prognosis<sup>11</sup>.

Chemokine is a peptide mediator that involved in normal cell development, immune regulation, hematopoietic regulation, wound healing process and inflammation, however overexpression in cancer cells may induce a negative effect. Increased chemokine plays a role in facilitating communication between cancer cells and neoplastic cells in the tumor microenvironment, including endothelial cells, fibroblast, neutrophil activation, and tumor-associated macrophages<sup>13</sup>. The chemokine CXCL12 (Chemokine C-X-C motif ligand 12) binds to its specific receptor, CXCR4 (Chemokine C-X-C motif receptor 4), which through various divergent pathways causes chemotaxis, thereby, increasing intracellular calcium, cell adhesion, cell survival, cell proliferation, and gene transcription<sup>14</sup>. The role of CXCL12/CXCR4 axis is commanded by cancer cells to facilitate the spread of CXCR4-containing tumor cells to highly CXCL12 concentrated tissue. The strong expression of CXCR4 in cancer cells contributes to tumor growth, invasion, angiogenesis, regional lymph node involvement, distant metastasis, relapse, and therapy resistance, leading to poor outcomes, including in ccRCC<sup>15,16</sup>.

Loss of VHL protein function in ccRCC will lead hypoxia condition in cells and HIF-1 $\alpha$  (Hypoxia-Inducible Factor 1 $\alpha$ ) accumulation, which will enhance CXCR4 expression<sup>14,17,18</sup>. Overexpression of CXCR4 is an important predictive and prognostic factor for disease progression, aggressiveness, and metastasis in ccRCC, as well as a potential target for anti-cancer therapy<sup>15,16,19</sup>. Overexpression of CXCR4 in cancer cells increase AKT and ERK phosphorylation, also induces the expression and activity of matrix-metalloproteinases (MMPs) such as MMP-2<sup>20,21,22</sup>.

One of the subgroups of MMPs is gelatinase, namely matrix metalloproteinase-2 (MMP-2), which plays a role in tumor invasion and metastasis by degrading type IV collagen, which is a major component of the basement membrane and extracellular matrix<sup>23</sup>. The expression and activity of MMP-2 is intensively studied, which often increased in human malignancies and positively correlated with tumor stage, lymph node involvement, increased distant metastasis, and poor prognosis<sup>24</sup>. Increased expression of CXCR4 and MMP-2 in tumor cells under VHL protein inactivation resulting in cell hypoxia may promote more aggressive tumor

progression<sup>23,25</sup>. To date, no study has been published regarding the correlation of CXCR4 and MMP-2 expression in clear cell renal cell carcinoma in Indonesia. This study was conducted to analyze the role and correlation of those biomarkers in a referral hospital in East Java, Indonesia.

## MATERIALS AND METHODS:

### Research Design and Sample:

This analytical observational study was conducted on archived formalin-fixed paraffin-embedded tissue samples obtained from 43 patients who underwent nephrectomy and diagnosed as clear cell renal cell carcinoma in Anatomical Pathology Laboratory of Dr. Soetomo General Academic Hospital, Surabaya, Indonesia, throughout January 2015 until December 2020. The clinical data comprising patient's gender and age obtained from medical record data. Medical records were also reviewed and documented regarding the data of tumor size and tumor extension into renal capsule, perirenal fat, renal sinus, renal pelvis, major renal vein, fascia Gerota, also ipsilateral adrenal gland. The pathological parameters in this study were T stage, CXCR4 expression and MMP-2 expression. All of the H&E-stained slides from each case were reviewed and tumors were histologically classified into 4 groups of T stage according to WHO/AJCC TNM classification for renal carcinoma: T1 (n=6), T2 (n=21), T3 (n=13), and T4 (n=3). Expression of CXCR4 and MMP-2 were evaluated using immunohistochemistry. Ethical approval for this research was issued by Ethics Committee of Dr. Soetomo General Academic Hospital, Surabaya, Indonesia (Reference number: 0482/LOE/301.4.2/VI/2021).

### Immunohistochemical Staining:

Immunohistochemical (IHC) staining was performed on 4- $\mu$ m-thick, formalin-fixed, paraffin-embedded tissue sections using microtome device (Leica Biosystems), placed on poly-L-Lysine coated glass slide, placed in hotplate (55°C) for 1 hour, left overnight in room temperature. Slides were dewaxed with xylenes 3 times, 5 minutes each, and then rehydrated through a gradual concentration series of alcohol, 2 minutes each. Antigen retrieval was processed with target retrieval solution/sodium citrate buffer in decloaking chamber at temperature 90°C for 45 minutes. Endogenous peroxidase and non-reactive background staining were blocked by 3% H<sub>2</sub>O<sub>2</sub> for 20 minutes at room temperature. Primary antibody with CXCR4 monoclonal antibody (1:100 dilution, CXCR4 [4G10]: sc-53534, Santa Cruz Biotechnology) and MMP-2 monoclonal antibody (1:100 dilution, MMP-2 [8B4]: sc-13595, Santa Cruz Biotechnology) were applied on all samples at 4°C, incubated overnight and then washed in tris-buffered saline. Secondary antibody was applied using biotin-streptavidin-peroxidase kit. A chromogen, 3,3'-

Diaminobenzidine, then applied for 15 minutes on all samples, washed with water, and then counterstained with Mayer's hematoxylin, dehydrated in alcohol gradual concentration series, cleared with xylenes, and finally mounted. Normal lung alveoli tissue was used for positive control of CXCR4 staining. Invasive breast carcinoma tissue was used for positive control of MMP-2 staining.

CXCR4 staining was observed on the cytoplasm, membrane, and nucleus of the tumor cells. MMP-2 staining was observed on the cytoplasm of the tumor cells. Both CXCR4 and MMP2 staining on tissue section was assessed at least on 1000 tumor cells with the highest density cells, using immunoreactive score (IRS) which is a semi-quantitative scoring system that considering the staining intensity and the extent of stained cells, that has been widely accepted and used in previous study<sup>18,26,27,28,29,30,31</sup>. The immunostaining intensity was scored as 0 (no staining), 1(weak), 2 (moderate), and 3(strong). The extent of immunostaining was scored as 0 (0%), 1(1% - 10%), 2 (>10% - 50%), 3(>50% - 80%), and 4(>80%). The final immunoreactive score was determined by multiplying the intensity score with the extent of positive stained cells score. The minimum score is 0 and the maximum score is 12. For statistical purpose, final immunoreactive score was classified into 4 groups. Score equal to or less than 1 was considered as negative, score 2 - 3 was considered as weak positive, score 4 - 5 was considered as moderate positive, and score 6 or more was considered as strong positive. Immunostaining evaluation was carried out using Olympus CX41RF light microscope at 400x magnification by 2 pathologists who were blinded to the patient's data and stage information, and also microscopically recorded using Olympus DP2-BSW. If scoring discrepancies were found between the observers, the slides were reevaluated and final interpretation determined. The concordance rate was more than 95% between the observers.

**Statistical Analysis:**

SPSS version 25.0 (IBM Corporation, Armonk, NY, USA) was utilized for all statistical analysis. Kruskal-Wallis test was used to analyze the expression difference of CXCR4 and MMP-2 in various T stages. Spearman's correlation test was used to analyze the correlation of

CXCR4 expression with various T stages, MMP-2 expression with various T stages, and CXCR4 expression with MMP-2 expression in various T stages. The significance of those statistical analysis results was confirmed when *p*-value is < 0.05.

**RESULTS:**

The patients were ranged from age 29 to 69 years old, with the average of patient's age was 53.60±9.63 years, and the highest age group was within 41-50 years group interval, amount for 16(37.2%) patients. Male sex was the majority against female, 30(69.8%) cases and 13 (30.2%) cases, respectively, with a ratio 2.3:1. The highest distribution of T stage was found on stage T2, counted for 21(48.8%) cases, followed by stage T3, T1, and T4. The clinicopathological characteristics of the samples are shown in Table 1.

**Table 1. Characteristic of clinicopathological profile**

Characteristics	n (%)	
Age	21 – 30 years	2 (4.7)
	31 – 40 years	0 (0)
	41 – 50 years	16 (37.2)
	51 – 60 years	12 (27.9)
	61 – 70 years	13 (30.2)
Sex	Male	30 (69.8)
	Female	13 (30.2)
T stage	T1	6 (14)
	T2	21 (48.8)
	T3	13 (30.2)
	T4	3 (7)

**CXCR4 expression in clear cell renal cell carcinoma:**


CXCR4 expression was found on the cytoplasm, membrane, or nucleus of tumor cells. This study evaluated the overall staining without differentiating the staining location. Tumor with positive strong staining showed a strong staining on the cell cytoplasm rather in membrane or nucleus (Figure 1). CXCR4 evaluation was carried out with immunoreactive score. Only 2 (4.7%) cases exhibited a negative CXCR4 expression, while 25 (58.1%) cases showed a strong positive expression. A significant difference of CXCR4 expression between various T stages was revealed with *p*-value = 0.016. Spearman correlation test revealed a highly significant positive correlation between CXCR4 expression and various T stages in ccRCC (*r<sub>s</sub>* = 0.48, *p* = 0.001). Statistical analysis results are shown on Table 2 and Figure 2.

**Table 2. Association between CXCR4 expression and T stage**



T Stage	CXCR4 expression				<i>p</i> -value <sup>a</sup>	<i>r<sub>s</sub></i> <sup>b</sup>	<i>p</i> -value <sup>b</sup>
	Negative n (%)	Weak Positive n (%)	Moderate Positive n (%)	Strong Positive n (%)			
T1	1 (16.7)	2 (33.3)	2 (33.3)	1 (16.7)	0.016	0.48	0.001
T2	1 (4.8)	2 (9.5)	7 (33.3)	11 (52.4)			
T3	0 (0)	0 (0)	3 (23.1)	10 (76.9)			
T4	0 (0)	0 (0)	0 (0)	3 (100)			

a: Kruskal Wallis test applied, *p*-value < 0.05 considered as significant.

b: Spearman correlation test applied, *p*-value < 0.05 considered as significant.




**Figure 1:** CXCR4 expression on tumor cells of clear cell renal cell carcinoma. The tumor cells were stained on cell cytoplasm, membrane, or nucleus (IHC, 400x magnification). A). Negative expression (IRS score 0 – 1). B). Weak positive expression (black arrow) (IRS score 2 – 3). C). Moderate positive expression (IRS score 4 – 5). D) Strong positive expression (IRS score  $\geq 6$ ) with strong cytoplasm staining. Black bar: 50  $\mu\text{m}$ .




**Figure 2.** Statistical analysis diagram of CXCR4 and T stage. A). Boxplot diagram of CXCR4 expression difference in various T stages. B) Scattered plot diagram of CXCR4 correlation with T stage in clear cell renal cell carcinoma.

#### MMP-2 expression in clear cell renal cell carcinoma:

MMP-2 expression was found on the cell cytoplasm (Figure 3). MMP-2 evaluation was carried out with immunoreactive score. Only 2 (4.7%) cases exhibited a negative MMP-2 expression, while 20 (46.5%) cases showed a strong positive expression. A significant difference of MMP-2 expression between various T stages was revealed with  $p$ -value = 0.029. Spearman correlation test revealed a highly significant positive correlation between MMP-2 expression and various T stages in ccRCC ( $r_s = 0.46$ ,  $p = 0.002$ ). Statistical analysis results are shown on Table 3 and Figure 4.



**Figure 3:** MMP-2 expression on tumor cells of clear cell renal cell carcinoma. The tumor cells were stained on cell cytoplasm (IHC, 400x magnification). A). Negative expression (IRS score 0 – 1). B). Weak positive expression (black arrow) (IRS score 2 – 3). C). Moderate positive expression (IRS score 4 – 5). D) Strong positive expression (IRS score  $\geq 6$ ) with strong cytoplasm staining. Black bar: 50  $\mu\text{m}$ .




**Table 3. Association between MMP-2 expression and T stage**

T Stage	MMP-2 expression				p-value <sup>a</sup>	r <sub>s</sub> <sup>b</sup>	p-value <sup>b</sup>
	Negative n (%)	Weak Positive n (%)	Moderate Positive n (%)	Strong Positive n (%)			
T1	1 (16.7)	2 (33.3)	2 (33.3)	1 (16.7)	0.029	0.46	0.002
T2	1 (4.8)	6 (28.6)	7 (33.3)	7 (33.3)			
T3	0 (0)	2 (15.4)	2 (15.4)	9 (69.2)			
T4	0 (0)	0 (0)	0 (0)	3 (100)			

a: Kruskal Wallis test applied, p-value < 0.05 considered as significant.

b: Spearman correlation

test applied, p-value < 0.05 considered as significant.



**Figure 4: Statistical analysis diagram of MMP-2 and T stage. A). Boxplot diagram of MMP-2 expression difference in various T stages. B) Scattered plot diagram of MMP-2 correlation with T stage in clear cell renal cell carcinoma.**

**Correlation between CXCR4 and MMP-2 expression in various T stages of clear cell renal cell carcinoma**

A highly significant positive correlation was revealed between CXCR4 and MMP-2 expression in various T stages of clear cell renal cell carcinoma ( $r_s = 0.79, p = 0.000$ ). Statistical analysis results are shown on Table 4.

**Table 4. Spearman’s correlation test result of association between CXCR4 expression and MMP-2 expression in clear cell renal cell carcinoma**

CXCR4 expression	MMP-2 expression	
	r <sub>s</sub>	0.79
p	0.000	
n	43	

**DISCUSSION:**

The total number of clear cell renal cell carcinoma cases within 6 years in this study was 43 patients. The average age of patients was 53.6 years, this result was different with previous investigation in America that obtained 64 years as the average patient’s age<sup>5</sup>, but slightly closer to previous study in Indonesia which found the highest age range of kidney cancer is between 51 – 65 years interval<sup>32</sup>. Most of ccRCC patients in this study was male (69.8%) and ratio male to female was 2.3:1. This finding is consistent with earlier investigations<sup>3,5,32</sup>. The

risk factors may be due to smoking habits, excessive alcohol consumption, hypertension, and occupational exposure to trichloroethylene industrial materials which are more common in men<sup>3,5</sup>.

Surveillance, Epidemiology, and End Results (SEER) data showed that most kidney cancer patients present with local stage conditions (65%), namely T1-T2 or TNM stage I-II<sup>11</sup>. This study found almost the same result, that the distribution of the most patients was in the T2 group (48.8%) and when combining T1 and T2, 62.8% of cases will be obtained. The classic symptoms of kidney cancer such as hematuria and low back pain at flank region are likely to prompt patients to seek medical attention.

Expression of CXCR4 in this study evaluated on all T stages of ccRCC, that stained on cell cytoplasm, membrane, or nucleus. Evaluation of CXCR4 count the overall staining without differentiate the staining location, however the majority staining located on cell cytoplasm or membrane and only a few samples stained on nucleus. Tumors with strong positive CXCR4 expression appeared to stain strongly on the cytoplasm of the tumor cells, compared to tumors with moderate or weak expression. The result of difference analysis showed that there was a significant difference of CXCR4 expression with various T stages, where as an increase in CXCR4 expression was synergistic with an increase in T stage. Only 4.7% cases exhibited a negative CXCR4 expression, while 95.3% showed positive expression and 58.1% cases showed a strong positive expression.

Previous study by Zagzag et al., was in line to this study which found that the majority of kidney cancer samples showed staining on the cytoplasm, only few samples on the nucleus and membrane<sup>18,33</sup>. On the other hand, a study by An et al., found that CXCR4 staining was predominantly on the nucleus of ccRCC cells and its expression correlate with tumor size<sup>34</sup>. Wang et al., found that renal cell carcinoma A-498 cells showed CXCR4 expression on the cell surface, 30-60 minutes after the cells were stimulated with CXCL12 resulted in rapidly loss cell surface expression, but its expression was completely diffused on cytoplasm and nucleus after



24 hours<sup>35</sup>. CXCR4 expression was found in 65.4% of ccRCC patients, with 36.8% of patients showing strong immunoreactivity and associated with a poor prognosis<sup>19</sup>. The results of this study, however, differ from study by Floranovic et al., who found that the positive expression of CXCR4 in both cytoplasm and tumor cell showed no difference with larger tumor size and tumor grade<sup>34,36</sup>.

VHL protein has the capacity to degrade HIF under normal oxygenation conditions<sup>37</sup>, resulting in HIF-dependent activation of CXCR4<sup>38</sup>. Another study showed that high expression of CXCR4 was found in the nucleus, cytoplasm, and tumor cell membranes that did not undergo necrosis in ccRCC, both in tumors with hereditary VHL syndrome and sporadically. Vascular cells in these tumors also express CXCR4. This suggests that the VHL-HIF-1 pathway regulates the expression of CXCR4 and its ligands. Hypoxia increases the expression of CXCR4 through the activation of HIF-1 in monocytes, macrophages, endothelium and cancer cells. These findings suggest that involvement of CXCR4 and CXCL12 occurs via autocrine and/or intracrine mechanisms<sup>18,39</sup>.

This study exhibited a highly significant correlation between CXCR4 expression and T stage. The CXCR4/CXCL12 axis has a critical role in therapy resistance in various ways, one of them is by directly causing survival, invasion of cancer cells and proliferation of tumor cells, further attracting bone marrow-derived myeloid cells which indirectly facilitate tumor recurrence and metastasis, and cause angiogenesis<sup>40,41,42</sup>. The result of this study is in line with the study by Balshy et al., that found strong positive expression of CXCR4 was associated with an increase in tumor size<sup>43</sup>. Study by An et al., who assessed the correlation of CXCR4 expression with tumor size and tumor necrosis in ccRCC found that there was a positive correlation between CXCR4 expression with primary tumor size and tumor necrosis, supporting that CXCR4 expression could influence tumor growth<sup>34</sup>. Wehler et al., found in their study that CXCR4 expression was correlated with T stage in renal cell carcinoma, where the researchers divided stage T into 2 groups, namely T1-2 and T3-4<sup>33</sup>. Otherwise, a study by D'Alterio et al., found that there was no correlation between CXCR4 expression and T stage in renal cell carcinoma<sup>44</sup>.

The role of CXCR4 in tumor growth initiation was confirmed by the role of CXCR4 antagonists that can inhibit tumor growth in several orthotopic experimental and subcutaneous human xenografts<sup>45,46,47,48</sup>. It supports the opportunity for targeted anti-CXCR4 therapy in various malignancies, such as low molecular weight

CXCR4 antagonist AMD3100 (Plerixafor) which continues developed in the trial phase on various cancers<sup>42,49,50</sup>.

The expression of MMP-2 in this study was observed in the four groups of T stages in ccRCC. Tumors with strong positive expression of MMP-2 were stained strongly on the cell cytoplasm. Only 4.7% cases exhibited a negative CXCR4 expression, while 95.3% showed positive expression and 46.5% cases showed a strong positive expression. All (100%) samples of stage T4 exhibited a strong positive expression whereas among stage T1 and T2 groups still showed a negative expression. A significant MMP-2 expression difference was obtained in various T stages. Some cases in this study showed stronger MMP-2 expression in tumor peripheral area that invaded the adjacent connective tissue stroma, compared to the central area of the tumor. This finding was in line with the literature which states that the integrity of the extracellular matrix surrounding tumor cells affects the behavior of the tumor and if disturbed, it can facilitate local invasion and distant metastatic spread<sup>51</sup>. Study by Kurban et al., found that highly invasive renal cell carcinoma with VHL inactivation showed increased levels and activity of MMP-2<sup>52</sup>.

A significant correlation between MMP-2 expression and T stage was found in this study. In contrast with a study on renal cell carcinoma by Kallakury et al., that found no correlation of MMP-2 expression with advanced stages (T3 and T4)<sup>54</sup>. Study by Ahmad et al., using body serum with the ELISA method also showed no correlation between MMP-2 expression and tumor size in renal cell carcinoma<sup>55</sup>. Nonetheless, this study is in line with melanoma research which found that MMP-2 expression was associated with tumor progression both primary and metastatic tumors<sup>53</sup>. Moreover, study in prostate cancer found that MMP-2 was expressed by tumor cells in 70% of cases and by stromal cells around the tumor in 75.9% of cases, which associated with Gleason score, T stage, and decreased disease-free survival<sup>56</sup>. Study in colorectal adenocarcinoma also shown a highly significant correlation between MMP-2 expression and T stage<sup>57</sup>.

MMP-2 plays an important role in kidney cancer growth, which predominantly degrades basement membrane components. The extracellular matrix supports tumor cell localization, facilitating communication between tumor cells and their stroma. The interaction between the VHL/HIF protein signaling axis and the activated kinase linkage results in aberrations in the extracellular matrix leading to tumor progression and invasion<sup>51,58</sup>. Regulation of the extracellular matrix in renal cell carcinoma occurs

through both HIF-dependent and HIF-independent pathways. Loss of VHL will result in downregulation of intercellular connective proteins that will contribute to increased motility and tumor cell invasion<sup>52</sup>. A positive correlation between strong MMP-2 expression and T stage in ccRCC can be used as a basis for second-line therapy of ccRCC after conventional therapy, such as chemotherapy or radiation with MMPs inhibitors such as Marastat and BMS-275291, or anti-MMP-2 VHH-29 which is recently being developed<sup>59,60,61</sup>.

A highly significant positive correlation between CXCR4 expression and MMP-2 expression was found in this study. This is consistent with the literature which states that increased expression of CXCR4 and MMP-2 in tumor cells in pVHL inactivation condition, can increase the potential for more aggressive tumor progression and metastasis dissemination<sup>25</sup>. Studies in ccRCC by Struckmann et al., with ccRCC 786-O VHL-null strain showed a strong relationship between CXCR4 and MMP-2. CXCR4 expression was found very strong in 786-O VHL-null tumor cells, with CXCR4 distribution mainly on the cell surface. MMP-2 expression was also found abundantly in 786-O cells. MMP-2 expression was found higher than MMP-9 expression in ccRCC tumor cells. Restoration of VHL function in these tumor cells showed a loss of CXCR4/CXCL12 expression as well as MMP-2/MMP-9 expression<sup>23</sup>. The results of previous studies are in line with this first study in Indonesia in analyzing the correlation of CXCR4 and MMP-2 in ccRCC, which statistical test results revealed a highly significant positive correlation between CXCR4 and MMP-2 expression at various T stages of ccRCC. This confirms the theory that VHL protein inactivation that occurred in most ccRCCs may promote a strong positive expression of CXCR4 and MMP-2, which will synergize with the proliferation, survival, growth, and migration of invasive tumor cells that will impact a worse prognosis.

## CONCLUSION:

The strong positive expression of CXCR4 and MMP2 are significant biomarkers of T stage in clear cell renal cell carcinoma. This study exhibited that CXCR4 and MMP-2 expression showed synergistic and positive correlation with T stage of clear cell renal cell carcinoma. The correlation of CXCR4 and MMP-2 overexpression with high T stage in clear cell renal cell carcinoma can be considered as the basis of targeted therapy.

## ACKNOWLEDGEMENTS:

The author expresses the gratitude to the Dean of Faculty of Medicine, Universitas Airlangga for the opportunity given to fulfil the specialist doctor education program and carry out this research, which is a part of

the renal cell carcinoma research tree of anatomical pathology research group. The author also expresses the gratitude to all lecturers in Department of Anatomical Pathology, Faculty of Medicine, Universitas Airlangga, Indonesia. We thank Dr. Budi Utomo, dr., M.Kes. in the statistical analysis.

## CONFLICT OF INTEREST:

The author declares no conflict of interest.

## REFERENCES:

1. Dharmawan MA, Ansori ANM, Dian FA, Probojati RT, Tamam MB, Kharisma VD. Vaccine construction for human papilloma virus (HPV) type 16 and 18 Infection using in silico approach to combat cervical cancer. *Genbinesia Journal of Biology*. 2021; 1(1): 13-22.
2. Padala, S.A., Barsouk, A., Thandra K.C., Saginala, K., Mohammed, A., Vakiti, A., Rawla, P., and Barsouk, A. 2020. 'Epidemiology of renal cell carcinoma'. *World J Oncol*, 11(3), pp. 79-87. doi:10.14740/wjon1279
3. Hakimi, A.A., Reznik, E., Lee, C., Creighton, C.J., Brannon, A.R., Luna, A., Aksoy, B.A., Liu, E.M., Shen, R., Lee, W., Chen, Y., Stirdivant, S.M., Russo, P., Chen, Y., Tickoo, S.K., Reuter, V.E., Cheng, E.H., Sander, C., and Hsieh, J.J. 2016. 'An integrated metabolic atlas of clear cell renal cell carcinoma'. *Cancer Cell*, 29(1), pp.104-116. doi: 10.1016/j.ccell.201512.004
4. GLOBOCAN. 2020. 'The global cancer observatory: cancer today'. Lyon, France: World Health Organization International Agency for Research on Cancer (IARC). <https://gco.iarc.fr/today>. Accessed March 2, 2021.
5. Hsieh, J.J., Purdue, M.P., Signoretti, S., Swanton, C., Albiges, L., Schmidinger, M., Heng, D.Y., Larkin, J., and Ficarra, V. 2017. 'Renal cell carcinoma'. *Nat Rev Dis Primers* 3, 17009(1). doi: 10.1038/nrdp.2017.9
6. Bergstrom, A., Hsieh, J.J., Lindbald, P., Lu, C.M, Cook, N.R., and Wolk, A. 2001. 'Obesity and renal cell cancer-a quantitative review'. *Br J Cancer*, 85(7), pp. 984-990. doi: 10.1054/bjoc.2001.2040
7. Ferlay, J., Steliarova-Foucher, E., Lortet-Tieulent, J., Rosso, C., Coebergh, J.W.W., Comber, H., Forman, D., and Bray, F. 2013. 'Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012'. *Eur J Cancer*, 49(6), pp. 1374-1403. doi: 10.1016/j.ejca.2012.12.027
8. Rini, B.I., Campbell, S.C., and Escudier, B. 2009. 'Renal cell carcinoma'. *Lancet*, 373, pp. 1119-32. doi: 10.1016/S0140-6736(09)60229-4
9. Brugarolas, J. 2014. 'Molecular genetics of clear-cell renal cell carcinoma'. *J Clin Oncol*, 32(18), pp.1968-1976. doi: 10.1200/JCO.2012.45.2003
10. Erdogan, F., Demirel, A., and Polat, O. 2004. 'Prognostic significance of morphologic parameters in renal cell carcinoma'. *Int J Clin Pract*, 58(4), pp. 333-336. doi: 10.1111/j.1368-5031.2004.00008.x
11. Taneja, K. and Williamson, S.R. 2018. 'Updates in pathologic staging and histologic grading of renal cell carcinoma'. *Surgical Pathology Clinics*, 11(4), pp.797-812. doi: 10.1016/j.path.2018.07.004
12. Rini, B.I., McKiernan, J.M., and Chang, S.S. 2017. 'Kidney'. *AJCC cancer staging manual*. 8th ed. Switzerland: Springer, pp.739-48.
13. Lombardi, L., Tavano, F., Morellia, F., Latiano, T.P., Sebastiano, P.D., and Maiello, E. 2013. 'Chemokine receptor CXCR4: Role in gastrointestinal cancer'. *Critical Reviews in Oncology/Hematology*, 88(3), pp.696-705. doi: 10.1016/j.critrevonc.2013.08.005
14. Chatterjee, S., Azad, B.B., and Nimmagadda, S. 2014. 'Chapter two-The intricate role of CXCR4 in cancer'. *Advances in Cancer*

- Research, 124, pp.31-82. doi:10.1016/B978-0-12-411638-2.00002-1
15. Richard, C.L., Tan, E.Y., and Blay, J. 2006. 'Adenosine upregulates CXCR4 and enhances the proliferative and migratory responses of human carcinoma cells to CXCL12/SDF-1 $\alpha$ '. *Int. J. Cancer*, 119(9), pp. 2044-53. doi: 10.1002/ijc.22084
  16. Rasti, A., Abolhasani, M., Zanjani L. S., Asgari, M., Mehrazma, M., and Madjd, Z. 2017. 'Reduced expression of CXCR4, a novel renal cancer stem cell marker, is associated with high-grade renal cell carcinoma. *J Cancer Res Clin Oncol*, 143, pp. 95-104. doi: 10.1007/s00432-016-2239-8
  17. Staller, P., Sulitkova, J., Lisztwan, J., Moch, H., Oakeley, E.J., and Krek, W. 2003. 'Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL'. *Nature*, 425(6955), pp. 307-11. doi: 10.1038/nature01874
  18. Zagzag, D., Krishnamachary, B., Yee, H., Okuyama, H., Chiriboga, L., Ali, M.A., Melamed, J., and Semenza, G.L. 2005. 'Stromal cell-derived factor-1 $\alpha$  and CXCR4 expression in hemangioblastoma and clear cell-renal cell carcinoma: von Hippel-Lindau loss-of-function induces expression of a ligand and its receptor'. *Cancer Res*, 65(14), pp.6178-6188. doi: 10.1158/0008-5472.CAN-04-4406
  19. Li, G., Badin, G., Zhao, A., Gentil-Perret, A., Tostain, J., Peoc'h, M., and Gigante, M. 2013. 'Prognostic value of CXCR4 expression in patients with clear cell renal cell carcinoma'. *Histology and Histopathology*, 28(9), pp.1217-1222.
  20. Scotton, C.J., Wilson, J.L., Milliken, D., Stamp, G., and Balkwill, F.R. 2001. 'Epithelial cancer cell migration'. *Cancer Res*, 61(13), pp. 4961-65.
  21. Ghosh, M.C., Makena, P.S., Gorantla, V., Sinclair, S.E., and Waters, C.M. 2012. 'CXCR4 regulates migration of lung alveolar epithelial cells through activation of Rac1 and matrix metalloproteinase-2'. *Am J Physiol Lung Cell Mol Physiol*, 302, pp. L846-L856. doi:10.1152/ajplung.00321.2011
  22. Zhu, X., Bai, Q., Lu, Y., Lu, Y., Zhu, L., Zhou, X., and Wu, L. 2016. 'Expression and function of CXCL12/CXCR4/CXCR7 in thyroid cancer'. *International Journal of Oncology*, 48(6), pp.2321-2329. doi:0.3892/ijo.2016.3485
  23. Struckmann, K., Mertz, K., Steu, S., Storz, M., Staller, P., Krek, W., Schraml, P., and Moch, H. 2008. 'pVHL co-ordinately regulates CXCR4/CXCL12 and MMP2/MMP9 expression in human clear-cell renal cell carcinoma'. *The Journal of Pathology*, 214(4), 464-71. doi: 10.1002/path.2310
  24. Hua, H., Li, M., Luo, T., Yin, Y., and Jiang, Y. 2011. 'Matrix metalloproteinases in tumorigenesis: an evolving paradigm'. *Cell. Mol. Life Sci.*, 68, pp.3853-3868. doi: 10.1007/s00018-011-0763-x
  25. Sleightholm, R.L., Neilsen, B.K., Li, J., Steele, M.M., Singh, R.K., Hollingsworth, M.A., and Oupicky, D. 2017. 'Emerging roles of the CXCL12/CXCR4 axis in pancreatic cancer progression and therapy'. *Pharmacology & Therapeutics*, 179, pp.158-170. doi: 10.1016/j.pharmthera.2017.05.012
  26. Akashi, T., Koizumi, K., Tsuneyama, K., Saiki, I., Takano, Y., and Fuse, H. 2008. 'Chemokine receptor CXCR4 expression and prognosis in patients with metastatic prostate cancer'. *Cancer Science*, 99(3), pp.539-542. doi:10.1111/j.1349-7006.2007.00712.x
  27. Sun, Y., Mao, X., Fan, C., Liu, C., Guo, A., Guan, S., Jin, Q., Li, B., Yao, F., and Jin, F. 2014. 'CXCL12-CXCR4 axis promotes the natural selection of breast cancer cell metastasis'. *Tumor Biol.*, 35, pp.7765-7773. doi:10.1007/s13277-014-1816-1
  28. Ottaiano, A., Santorsola, M., Del Prete, P., Perri, F., Scala, S., Caraglia, M., and Nasti, G. 2021. 'Prognostic significance of CXCR4 in colorectal cancer: An updated meta-analysis and critical appraisal'. *Cancers*, 13, pp. 3284. doi:10.3390/cancers13133284
  29. Guntamo, N.C., Rahaju, A.S., and Kurniasari, N. 2021. 'The role of MMP-9 and VEGF in the invasion state of bladder urothelial carcinoma'. *Indones Biomed*, 13(1), pp.61-67. doi: 10.18585/inabj.v13i1.1348
  30. Hambalie, L.A., Rahaju, A.S., and Mastutik, G. 2021. 'The correlation of EMMPRIN and EGFR overexpression toward muscle invasiveness in urothelial carcinoma of bladder'. *Indian Journal of forensic medicine & toxicology*, 15(2), pp.2709-2715.
  31. Ramadhani, V.Y., Rahaju, A.S., and Kurniasari, N. 2021. 'The role of EMPPRIN in perirenal fat invasion clear cell renal cell carcinoma'. *Indian Journal of Forensic Medicine & Toxicology*, 15(1), pp.1633-1639.
  32. Hamid, A.R.A.H., Umbas, R., Oka, A.A.G., Mochtar, C.A., Djatisoesanto, W., Soedarso, M.A., Safriadi, F., Danarto, H.R., Warli, S.M., Ali, A.Z., Seputra, K.P., Sihombing, A.T., and Hakim, L. 2019. *Pedoman Tata Laksana Kanker Ginjal*. 2nd ed. DKI Jakarta: Ikatan Ahli Urologi Indonesia (IAUI).
  33. Wehler, T.C., Graf, C., Biesterfeld, S., Brenner, W., Schadt, J., Gockel, I., Berger, M.R., Thüroff, J.W., Galle, P.R., Moehler, M., and Schimanski, C.C. 2008. 'Strong expression of chemokine receptor CXCR4 by renal cell carcinoma correlates with advanced disease'. *Journal of Oncology*, ID 626340, pp.1-6. doi:10.1155/2008/626340
  34. An, H., Xu, L., Zhu, Y., Lv, T., Liu, W., Liu, Y., Liu, H., Chen, L., Xu, J., and Lin, Z. 2014. 'High CXC chemokine receptor 4 expression is an adverse prognostic factor in patients with clear-cell renal cell carcinoma'. *Br J Cancer*, 110, pp. 2261-2268. doi: 10.1038/bjc.2014.179
  35. Wang, L., Wang, Z., Yang, B., Yang, Q., Wang, L., and Sun, Y. 2009. 'CXCR4 nuclear localization follows binding of its ligand SDF-1 and occurs in metastatic but not primary renal cell carcinoma'. *Oncology Reports*, 22, pp.1333-1339. [https://doi.org/10.3892/or\\_00000572](https://doi.org/10.3892/or_00000572)
  36. Floranović, M.P., Petrović, A.R., Veličković, F., and Veličković, L.J. 2021. 'Expression and prognostic value of CXCL12/CXCR4/CXCR7 axis in clear cell renal cell carcinoma'. *Clin Exp Nephrol*, 25, pp.1057-1069. doi:10.1007/s10157-021-02081-0
  37. Octavianda, Y. and Rahaju, A.S. 2018. 'Increased HIF-1 $\alpha$  and VEGF expression found in various T stages of clear cell renal cell carcinoma'. *Folia Medica Indonesiana*, 54(2), pp.102-107. doi: 10.20473/fmi.v54i2.8858
  38. Du, Y., Long, Q., Guan, B., and Mu, L. 2015. 'Prognostic value of high CXCR4 expression in renal cell carcinoma: A system review and meta-analysis'. *Disease Markers*, 2015(568980). doi: 10.1155/2015/568980
  39. Bachelder, R.E., Wendt, M.A., and Mercurio, A.M. 2002. 'Vascular endothelial growth factor promotes breast carcinoma invasion in an autocrine manner by regulating the chemokine receptor CXCR4'. *Cancer Res*, 62(24), pp. 7203-7206.
  40. Teicher, B.A. and Fricker, P.S. 2010. 'CXCL12(SDF-1)/CXCR4 pathway in cancer'. *Clin Cancer Res*, 16(11), pp. 2927-2931. doi: 10.1158/1078-0432.CCR-09-2329
  41. Duda, D.G., Kozin, S.V., Kirkpatrick, N.D., Xu, L., Fukumura, D., and Jain, R.K. 2011. 'CXCL12 (SDF1 $\alpha$ )-CXCR4/CXCR7 pathway inhibition: An emerging sensitizer for anticancer therapies?'. *Clin Cancer Res*, 17(8), pp.2074 -2080. doi: 10.1158/1078-0432.CCR-10-2636
  42. Santagata, S., Ieranò, C., Trotta, A.M., Capilungo, A., Auletta, F., Guardascione, G., and Scala, S. 2021. 'CXCR4 and CXCR7 signaling pathways: A focus 83 on the cross-talk between cancer cells and tumor microenvironment'. *Oncol*, 11, pp.591386. doi:10.3389/fonc.2021.591386
  43. Balshy, A.E.E., Maksoud, A.A.E., Sawi, R.E., and Nagieb, Y. 2021. 'Significance of CXC chemokine receptor 4 (CXCR4) in Renal Cell Carcinoma'. *Benha Medical Journal*, 38(6), pp.73-91. doi: 10.21608/bmfj.2020.125160
  44. D'Alterio, C., Cindolo, L., Portella, L., Polimeno, M., Consales, C., Riccio, A., Cioffi, M., Franco, R., Chiodini, P., Carteni, G., Mirone, V., Longo, N., Marra, L., Perdonà, S., Claudio, L., Mascolo, M., Staibano, S., Falsaperla, M., Puglisi, M., Martignoni, G., Ficarra, V., Castello, G., and Scala, S. 2010a. 'Differential role of CD133 and CXCR4 in renal cell carcinoma'. *Cell Cycle*, 9(22), pp.4492-4500. doi: 10.4161/cc.9.22.13680

45. Smith, M.C., Luker, K.E., Garbow, J.R., Prior, J.L., Jackson, E., Piwnica-Worms, D., and Luker, G.D. 2004. 'CXCR4 regulates growth of both primary and metastatic breast cancer'. *Cancer Res*, 64(23), pp.8604–8612
46. De Falco, V., Guarino, V., Avilla, E., Castellone, M.D., Salerno, P., Salvatore, G., Faviana, P., Basolo, F., Santoro, M., and Melillo, R.M. 2007. 'Biological role and potential therapeutic targeting of the chemokine receptor CXCR4 in undifferentiated thyroid cancer'. *Cancer Res*, 67(24), pp.11821-11829. doi: 10.1158/0008-5472.CAN-07-0899
47. Porvasnik, S., Sakamoto, N., Kusmartsev, S., Eruslanov, E., Kim, W.J., Cao, W., Urbanek, C., Wong, D., Goodison, S., and Rosser, C.J. 2009. 'Effects of CXCR4 antagonist CTCE-9908 on prostate tumor growth'. *Prostate*, 69(13), pp.1460–1469. doi:10.1002/pros.21008
48. Cho, K.S., Yoon, S.J., Lee, J.Y., Cho, N.H., Choi, Y.D., Song, Y.S., and Hong, S.J. 2013. 'Inhibition of tumor growth and histopathological changes following treatment with a chemokine receptor CXCR4 antagonist in a prostate cancer xenograft model'. *Oncol Lett*, 6(4), 933–938.
49. De Clercq, E. 2010. 'Recent advances on the use of the CXCR4 antagonist plerixafor (AMD3100, Mozobil™) and potential of other CXCR4 antagonists as stem cell mobilizers'. *Pharmacology & Therapeutics*, 128(3), pp.509–518. doi: 10.1016/j.pharmthera.2010.08.009
50. Fricker, S.P., Anastassov, V., Cox, J., Darkes, M.C., Grujic, O., Idzan, S.R., Labrecque, J., Lau, G., Mosi, R.M., Nelson, K.L., Qin, L., Santucci, Z., and Wong, R.S.Y. 2006. 'Characterization of the molecular pharmacology of AMD3100: A specific antagonist of the G-protein coupled chemokine receptor, CXCR4'. *Biochemical Pharmacology*, 72(5), pp.588–596. doi:10.1016/j.bcp.2006.05.010
51. Rosadi I, Karina K, Kharisma VD, Ansori ANM. L-ascorbic acid-2-phosphate and fibrin substrate enhances the chondrogenic differentiation of human adipose-derived stem cells. *Progress in Stem Cell*. 2021; 8(2): 310-317.
52. Kurban, G., Hudon, V., Duplan, E., Ohh, M., Pause, A. 2006. 'Characterization of a von Hippel Lindau pathway involved in extracellular matrix remodeling, cell invasion, and angiogenesis'. *Cancer Res* 66, pp. 1313–1319. doi: 10.158/0008-5472.CAN-05-2560
53. Rotte, A., Martinka, M., and Li, G. 2012. 'MMP2 expression is a prognostic marker for primary melanoma patients'. *Cell Oncol*, 35, pp.207-216. doi: 10.1007/s13402-012-0080-x
54. Kallakury, B.V., Karikhehalli, S., Haholu, A., Sheehan, C.E., Ami, N., and Ross, J.S. 2001. 'Increased expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinases 1 and 2 correlate with poor prognostic variables in renal cell carcinoma'. *Clin Cancer Res*, 7, pp. 3113–3119.
55. Ahmad, S., Singh, V., Sinha, R.J., Srivastava, A., and Mandhani, A. 2018. 'Role of MMP-2, MMP-9 and VEGF as serum biomarker in early prognosis of renal cell carcinoma'. *African Journal of Urology*, 24, pp.255-263. doi: 10.1016/j.afju.2018.09.003
56. Trudel, D., Fradet, Y., Meyer, F., Harel, F., and Tetu, B. 2003. 'Significance of MMP-2 expression in prostate cancer: an immunohistochemical study'. *Cancer Research*, 63, pp.8511-8515.
57. Fatimah, S., Rahaju, A.S., and Rahniayu, A. 2021. 'Role of Claudin-4 and Matrix Metalloproteinase-2 in tumor invasion of colorectal adenocarcinoma'. *Research J. Pharm. and Tech.*, 14(9), pp.4795-4800. doi: 10.52711/0974-360X.2021.00834
58. Nagase, H., Visse, R., and Murphy, G. 2006. 'Structure and function of matrix metalloproteinases and TIMPs'. *Cardiovasc Res*, 69(3), pp. 562–573. doi: 10.1016/j.cardiores.2005.12.002
59. Miller, K.D., Saphner, T.J., Waterhouse, D.M., Chen, T.-T., Rush-Taylor, A., Sparano, J.A., Wolff, A.C., Cobleigh, M.A., Galbraith, S., and Sledge, G.W. 2004. 'A randomized phase II feasibility trial of BMS-275291 in patients with early breast cancer'. *Clin Cancer Res*, 10(6), pp.1971-1975. doi: 10.1158/1078-0432.CCR-03-0968
60. Leigh, N.B., Paz-Ares, L., Douillard, J.-Y., Peschel, C., Arnold, A., Depierre, A., Santoro, A., Betticher, D.C., Gatzemeier, U., Jassem, J., Crawford, J., Tu, D., Bezjak, A., Humphrey, J.S., Voi, M., Galbraith, S., Hann, K., Seymour, L., and Shepherd, F.A. 2005. 'Randomized phase III study of matrix metalloproteinase inhibitor BMS-275291 in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: National cancer institute of Canada-clinical trials group study BR.18'. *J Clin Oncol*, 23, pp.2831-2839. doi: 10.1200/JCO.2005.04.044
61. Widyananda MH, Pratama SK, Samoedra RS, Sari FN, Kharisma VD, Ansori ANM, Antonius Y. Molecular docking study of sea urchin (*Arbacia lixula*) peptides as multi-target inhibitor for non-small cell lung cancer (NSCLC) associated proteins. *J Pharm Pharmacogn Res*. 2021; 9(4): 484-96.
62. Ramadhani NF, Nugraha AP, Ihsan IS, Agung YA, Rantam FA, Ernawati DS, Ridwan RD, Narmada IB, Ansori AN, Hayaza S, Noor TN. Gingival medicinal signaling cells conditioned medium effect on the osteoclast and osteoblast number in lipopolysaccharide-induced calvaria bone resorption in wistar rats' (*Rattus norvegicus*). *Research Journal of Pharmacy and Technology*. 2021; 14(10): 5232-7.
63. Frayyeh, A.H., Salman, E.D., and Melconian, A.K. 2019. 'Elevated serum level of CXCR4 in breast cancer women'. *Research J. Pharm. and Tech.*, 12(8), pp. 3833-3838.
64. Fadholly A, Ansori AN, Proboningrat A, Nugraha AP, Iskandar RP, Rantam FA, Sudjarwo SA. Apoptosis of hela cells via caspase-3 expression induced by chitosan-based nanoparticles of *Annona squamosa* leaf extract: In vitro study. *Indian J. Pharm. Educ. Res*. 2020; 54(2): 416-22.
65. Fadholly A, Ansori AN, Susilo RJ, Nugraha AP. *Daphne genkwa* sieb. et zucc. as anticancer of oral squamous cell carcinoma: A systematic review. *Biochemical and Cellular Archives*. 2020; 20: 2849-55.
66. Proboningrat A, Ansori AN, Fadholly A, Putri N, Kusala MK, Achmad AB. First report on the cytotoxicity of *Pinus merkusii* bark extract in WiDr, A human colon carcinoma cell line. *Research Journal of Pharmacy and Technology*. 2021; 14(3): 1685-8.
67. Pandey, P., and Kar, P.K. 2013. 'Assessment of suitability of methods used in the diagnosis of carcinomas'. *Research J. Pharmacology and Pharmacodynamics*, 5(2), pp. 98-100.
68. Proboningrat A, Jayanti S, Fadholly A, Ansori AN, Putri N, Kusala MK, Sudjarwo SA, Rantam FA, Achmad AB. The cytotoxicity of ethanolic extract of *Allium cepa* L. on hela cell lines. *Research Journal of Pharmacy and Technology*. 2021; 14(9): 4969-72.
69. Fadholly A, Ansori AN, Jayanti S, Proboningrat A, Kusala MK, Putri N, Rantam FA, Sudjarwo SA. Cytotoxic effect of *Allium cepa* L. extract on human colon cancer (WiDr) cells: in vitro study. *Research Journal of Pharmacy and Technology*. 2019; 12(7): 3483-6.
70. Fadholly A, Ansori ANM, Utomo B. Anticancer effect of naringin on human colon cancer (widr cells): In vitro study. *Research Journal of Pharmacy and Technology*. 2022; 15(2):885-8. doi: 10.52711/0974-360X.2022.00148





# Source details

## Research Journal of Pharmacy and Technology

Scopus coverage years: 1997, 2005, from 2011 to Present

Publisher: A and V Publication

ISSN: 0974-3618 E-ISSN: 0974-360X

Subject area: Pharmacology, Toxicology and Pharmaceutics: Pharmacology, Toxicology and Pharmaceutics (miscellaneous)

Medicine: Pharmacology (medical)

Source type: Journal

CiteScore 2022

1.3



SJR 2022

0.267



SNIP 2022

0.680



[View all documents >](#)

[Set document alert](#)

[Save to source list](#)

[CiteScore](#) [CiteScore rank & trend](#) [Scopus content coverage](#)

### Improved CiteScore methodology

CiteScore 2022 counts the citations received in 2019-2022 to articles, reviews, conference papers, book chapters and data papers published in 2019-2022, and divides this by the number of publications published in 2019-2022. [Learn more >](#)

CiteScore 2022

$$1.3 = \frac{4,962 \text{ Citations 2019 - 2022}}{3,848 \text{ Documents 2019 - 2022}}$$

Calculated on 05 May, 2023

CiteScoreTracker 2023

$$1.4 = \frac{5,685 \text{ Citations to date}}{4,021 \text{ Documents to date}}$$

Last updated on 05 April, 2024 • Updated monthly

## CiteScore rank 2022

Category	Rank	Percentile
Pharmacology, Toxicology and Pharmaceutics	#17/32	48th
Pharmacology, Toxicology and Pharmaceutics (miscellaneous)		
Medicine	#188/260	27th

[View CiteScore methodology >](#) [CiteScore FAQ >](#) [Add CiteScore to your site &](#)

# Research Journal of Pharmacy and Technology

## COUNTRY

India



Universities and research  
institutions in India

## SUBJECT AREA AND CATEGORY

Medicine  
Pharmacology (medical)  
Pharmacology, Toxicology and  
Pharmaceutics  
Pharmacology, Toxicology and  
Pharmaceutics  
(miscellaneous)

## PUBLISHER

A and V Publication

## H-INDEX

47

## PUBLICATION TYPE

Journals

## ISSN

0974360X, 09743618

## COVERAGE












1997, 2005, 2011-2021

## INFORMATION

[Homepage](#)  
[How to publish in this journal](#)  
[editor.rjpt@gmail.com](mailto:editor.rjpt@gmail.com)

## SCOPE

Research Journal of Pharmacy and Technology (RJPT) is an international, peer-reviewed, multidisciplinary journal, devoted to pharmaceutical sciences. The aim of RJPT is to increase the impact of pharmaceutical research both in academia and industry, with strong emphasis on quality and originality. RJPT publishes Original Research Articles, Short Communications, Review Articles in all areas of pharmaceutical sciences from the discovery of a drug up to clinical evaluation. Topics covered are: Pharmaceutics and Pharmacokinetics; Pharmaceutical chemistry including medicinal and analytical chemistry; Pharmacognosy including herbal products standardization and Phytochemistry; Pharmacology: Allied sciences including drug regulatory affairs, Pharmaceutical Marketing, Pharmaceutical Microbiology, Pharmaceutical biochemistry, Pharmaceutical Education and Hospital Pharmacy.



**Research Journal of Pharmacy and Technology**

**Q2** Pharmacology, Toxicology and Pharmaceutics... best quartile


**SJR 2023**  
0.27

powered by scimagojr.com

Show this widget in your own website

Just copy the code below and paste within your html code:

```
<a href="https://www.scima
```




**SURAT EXEMPTION**  
**(“ LETTER OF EXEMPTION ”)**

Ref. No. : 0482/LOE/301.4.2/VI/2021

Judul Protokol Penelitian : Korelasi Antara Ekspresi CXCR4 dan MMP-2 dengan Stadium T pada Karsinoma Sel Ginjal Tipe Clear Cell  
Dokumen yang disetujui : 0734/120/4/V/2021 (versi: 5)  
Tanggal terbit : 3 Juni 2021  
Berlaku sampai : 3 Juni 2022  
Peneliti Utama : Anny Setijo Rahaju, dr., Sp.PA (K)  
Peneliti Lain : 1. Pamela Kusumadewi Putri Thaib, dr  
2. Etty Hary Kusumastuti, dr., Sp.PA (K).FIAC  
Instalasi/Tempat Penelitian : RSUD Dr. Soetomo

Komite Etik Penelitian Kesehatan RSUD Dr Soetomo menyatakan bahwa dokumen diatas sesuai dengan The Office for Human Research Protections (OHRP) dibawah persyaratan the U.S. Department of Health and Human Services (HHS) Regulasi 45 CFR bagian 46 untuk **exempt review**.



Prof. Dr. Hendy Hendarto dr., SpOG(K)

Ketua Panel 1

Dra. Siti Farida SpFRS, Apt

Sekretaris Panel 1